WO2016162456A1 - Phospholipase c - Google Patents
Phospholipase c Download PDFInfo
- Publication number
- WO2016162456A1 WO2016162456A1 PCT/EP2016/057690 EP2016057690W WO2016162456A1 WO 2016162456 A1 WO2016162456 A1 WO 2016162456A1 EP 2016057690 W EP2016057690 W EP 2016057690W WO 2016162456 A1 WO2016162456 A1 WO 2016162456A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- phospholipids
- nucleic acid
- phospholipase
- sequence
- Prior art date
Links
- 108010079194 Type C Phospholipases Proteins 0.000 title claims abstract description 71
- 102000014384 Type C Phospholipases Human genes 0.000 title claims abstract description 70
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 189
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 186
- 229920001184 polypeptide Polymers 0.000 claims abstract description 185
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 92
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 74
- 230000000694 effects Effects 0.000 claims abstract description 70
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 64
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 64
- 238000000034 method Methods 0.000 claims abstract description 49
- 239000000203 mixture Substances 0.000 claims abstract description 44
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 37
- 239000008158 vegetable oil Substances 0.000 claims abstract description 36
- 230000008569 process Effects 0.000 claims abstract description 31
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 28
- 239000010452 phosphate Substances 0.000 claims abstract description 28
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 23
- -1 phosphate ester Chemical class 0.000 claims abstract description 17
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 16
- 108091026890 Coding region Proteins 0.000 claims abstract description 14
- 230000000295 complement effect Effects 0.000 claims abstract description 12
- 150000001982 diacylglycerols Chemical class 0.000 claims abstract description 4
- 102000004190 Enzymes Human genes 0.000 claims description 32
- 108090000790 Enzymes Proteins 0.000 claims description 32
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 29
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 27
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 27
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 26
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 26
- 238000000855 fermentation Methods 0.000 claims description 14
- 230000004151 fermentation Effects 0.000 claims description 14
- 239000013604 expression vector Substances 0.000 claims description 13
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 9
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 9
- 230000003301 hydrolyzing effect Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 60
- 239000003921 oil Substances 0.000 description 37
- 235000019198 oils Nutrition 0.000 description 37
- 102000015439 Phospholipases Human genes 0.000 description 32
- 108010064785 Phospholipases Proteins 0.000 description 32
- 239000000523 sample Substances 0.000 description 30
- 229940088598 enzyme Drugs 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 29
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 25
- 108091033319 polynucleotide Proteins 0.000 description 22
- 102000040430 polynucleotide Human genes 0.000 description 22
- 239000002157 polynucleotide Substances 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 150000001413 amino acids Chemical group 0.000 description 20
- 239000013598 vector Substances 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 239000000463 material Substances 0.000 description 16
- 241000228245 Aspergillus niger Species 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 241000499912 Trichoderma reesei Species 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000003549 soybean oil Substances 0.000 description 12
- 235000012424 soybean oil Nutrition 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- 230000007062 hydrolysis Effects 0.000 description 11
- 238000006460 hydrolysis reaction Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 230000007935 neutral effect Effects 0.000 description 11
- 238000005119 centrifugation Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 239000006185 dispersion Substances 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 7
- 241001149558 Trichoderma virens Species 0.000 description 7
- 230000002255 enzymatic effect Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 240000006439 Aspergillus oryzae Species 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- NAIXASFEPQPICN-UHFFFAOYSA-O p-nitrophenylphosphocholine Chemical compound C[N+](C)(C)CCOP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 NAIXASFEPQPICN-UHFFFAOYSA-O 0.000 description 6
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 5
- 108091005461 Nucleic proteins Proteins 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 235000019484 Rapeseed oil Nutrition 0.000 description 5
- 229920004890 Triton X-100 Polymers 0.000 description 5
- 239000013504 Triton X-100 Substances 0.000 description 5
- 235000013365 dairy product Nutrition 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- 241000228212 Aspergillus Species 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108010008885 Cellulose 1,4-beta-Cellobiosidase Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102100022624 Glucoamylase Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 238000007670 refining Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 229910000368 zinc sulfate Inorganic materials 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241001513093 Aspergillus awamori Species 0.000 description 3
- 108010084185 Cellulases Proteins 0.000 description 3
- 102000005575 Cellulases Human genes 0.000 description 3
- 108700010070 Codon Usage Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 241000223221 Fusarium oxysporum Species 0.000 description 3
- 241000567178 Fusarium venenatum Species 0.000 description 3
- 101150108358 GLAA gene Proteins 0.000 description 3
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 3
- 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 108020002496 Lysophospholipase Proteins 0.000 description 3
- 102100037883 Phospholipase B1, membrane-associated Human genes 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 241000959173 Rasamsonia emersonii Species 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 102000004139 alpha-Amylases Human genes 0.000 description 3
- 108090000637 alpha-Amylases Proteins 0.000 description 3
- 229940024171 alpha-amylase Drugs 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- JEJLGIQLPYYGEE-UHFFFAOYSA-N 1,2-dipalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCC JEJLGIQLPYYGEE-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 238000004679 31P NMR spectroscopy Methods 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 241000351920 Aspergillus nidulans Species 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101100083853 Homo sapiens POU2F3 gene Proteins 0.000 description 2
- 102100027612 Kallikrein-11 Human genes 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 2
- 101100058850 Oryza sativa subsp. japonica CYP78A11 gene Proteins 0.000 description 2
- 101150059175 PLA1 gene Proteins 0.000 description 2
- 102100026466 POU domain, class 2, transcription factor 3 Human genes 0.000 description 2
- 102000011420 Phospholipase D Human genes 0.000 description 2
- 108090000553 Phospholipase D Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000235403 Rhizomucor miehei Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 2
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 101710152431 Trypsin-like protease Proteins 0.000 description 2
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003518 caustics Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000105 evaporative light scattering detection Methods 0.000 description 2
- 108010038658 exo-1,4-beta-D-xylosidase Proteins 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 238000009616 inductively coupled plasma Methods 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012092 media component Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 2
- 150000003014 phosphoric acid esters Chemical class 0.000 description 2
- 229950004354 phosphorylcholine Drugs 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- OXFUXNFMHFCELM-UHFFFAOYSA-N tripropan-2-yl phosphate Chemical compound CC(C)OP(=O)(OC(C)C)OC(C)C OXFUXNFMHFCELM-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000009875 water degumming Methods 0.000 description 2
- GFAZGHREJPXDMH-UHFFFAOYSA-N 1,3-dipalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCC GFAZGHREJPXDMH-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 108010037870 Anthranilate Synthase Proteins 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- 241000892910 Aspergillus foetidus Species 0.000 description 1
- 101000756530 Aspergillus niger Endo-1,4-beta-xylanase B Proteins 0.000 description 1
- 241000131386 Aspergillus sojae Species 0.000 description 1
- 101100317631 Aspergillus tubingensis xynA gene Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000123346 Chrysosporium Species 0.000 description 1
- 241001674013 Chrysosporium lucknowense Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 240000003133 Elaeis guineensis Species 0.000 description 1
- 235000001950 Elaeis guineensis Nutrition 0.000 description 1
- 108010001817 Endo-1,4-beta Xylanases Proteins 0.000 description 1
- 101710132690 Endo-1,4-beta-xylanase A Proteins 0.000 description 1
- 108700005088 Fungal Genes Proteins 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- UXDDRFCJKNROTO-UHFFFAOYSA-N Glycerol 1,2-diacetate Chemical compound CC(=O)OCC(CO)OC(C)=O UXDDRFCJKNROTO-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PKVZBNCYEICAQP-UHFFFAOYSA-N Mecamylamine hydrochloride Chemical compound Cl.C1CC2C(C)(C)C(NC)(C)C1C2 PKVZBNCYEICAQP-UHFFFAOYSA-N 0.000 description 1
- 241000226677 Myceliophthora Species 0.000 description 1
- 238000013494 PH determination Methods 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000006486 Phosphoinositide Phospholipase C Human genes 0.000 description 1
- 108010044302 Phosphoinositide phospholipase C Proteins 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- 101710096328 Phospholipase A2 Proteins 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 241000678519 Rasamsonia Species 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000187432 Streptomyces coelicolor Species 0.000 description 1
- 101100370749 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) trpC1 gene Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 241000228341 Talaromyces Species 0.000 description 1
- 241001313536 Thermothelomyces thermophila Species 0.000 description 1
- 241001494489 Thielavia Species 0.000 description 1
- 241001495429 Thielavia terrestris Species 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 241001557886 Trichoderma sp. Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010048241 acetamidase Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 108010089934 carbohydrase Proteins 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 108010025790 chlorophyllase Proteins 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 108010091371 endoglucanase 1 Proteins 0.000 description 1
- 108010091384 endoglucanase 2 Proteins 0.000 description 1
- 108010092413 endoglucanase V Proteins 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 101150073906 gpdA gene Proteins 0.000 description 1
- 101150095733 gpsA gene Proteins 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 108010002430 hemicellulase Proteins 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- QCAWEPFNJXQPAN-UHFFFAOYSA-N methoxyfenozide Chemical compound COC1=CC=CC(C(=O)NN(C(=O)C=2C=C(C)C=C(C)C=2)C(C)(C)C)=C1C QCAWEPFNJXQPAN-UHFFFAOYSA-N 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- WVLBCYQITXONBZ-UHFFFAOYSA-N trimethyl phosphate Chemical compound COP(=O)(OC)OC WVLBCYQITXONBZ-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 101150016309 trpC gene Proteins 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 101150077833 xlnA gene Proteins 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B3/00—Refining fats or fatty oils
- C11B3/003—Refining fats or fatty oils by enzymes or microorganisms, living or dead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
- C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
- C12P7/18—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic polyhydric
- C12P7/20—Glycerol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04003—Phospholipase C (3.1.4.3)
Definitions
- the present invention relates to a polypeptide having phospholipase C activity and a process for degumming a vegetable oil.
- Phospholipases are a group of enzymes that catalyze the cleavage of phospholipids. There are several types of phospholipases. Phospholipase A1 (PLA1 ) removes the 1 -position fatty acid from the phospholipid to produce a free fatty acid and a 1 -lyso-2-acylphospholipid. Phospholipase B (PLB) hydrolyses both fatty acids leading to a glycerophosphate compound and two fatty acids, also known as lysophospholipase, and is considered an enzyme with a combination of both PLA1 and PLA2 activities.
- PHA1 Phospholipase A1
- Phospholipase B hydrolyses both fatty acids leading to a glycerophosphate compound and two fatty acids, also known as lysophospholipase, and is considered an enzyme with a combination of both PLA1 and PLA2 activities.
- Phospholipase C cleaves the glycerophosphate bond of phospholipids to produce a 1 ,2-diacylglycerol (DAG) and a phosphate or a phosphate ester (such as choline phosphate, ethanolamine phosphate and inositol phosphate).
- DAG 1 ,2-diacylglycerol
- Phospholipase D produces 1 ,2-diacylglycerophosphate, also known as phosphatidic acid, and a base group.
- Phospholipases are used amongst others in the refining or degumming of vegetable oils.
- the degumming of vegetable oils is performed by hydrating the phospholipids in the oil by water, followed by separation of the phospholipids by for instance centrifugation. Alternatively also acid and/or caustic treatments may be used to optimize the separation.
- the removal of phospholipids causes substantial loss of oil during the refining of vegetable oils.
- the use of enzymatic treatment of phospholipids reduces the oil losses associated with traditional oil degumming methods.
- Phospholipase C (PLC) is in such separation particularly useful as it creates a diglyceride from the phospholipid, which adds to the neutral oil yield, and it breaks the emulsifying power of phospholipid, which results in less oil loss to the gum phase.
- Phospholipase A1 or A2 is compared to PLC less advantageous as it creates a lysophospholipid and a fatty acid. The latter still needs to be removed in an extra step further downstream in the refining process, and the lysophospholipid still has emulsifying power and will still absorb some neutral oil in the gum phase.
- Extended overviews of enzymatic oil degumming processes can be found in F. Galhardo and C. Dayton (2012), Enzymatic Degumming, in AOCS Lipid Library (http://lipidlibrarv-aocs.orq/processinq/dequm-enz/index.htrri), and A. J. Dijkstra, 'Enzymatic degumming' in: Eur. J. Lipid Sci. Technol. 2010, 1 12, 1 178-1 189.
- the major phospholipids in vegetable seed oils are phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA) and phosphatidyl inositol (PI).
- PC phosphatidylcholine
- PE phosphatidylethanolamine
- PA phosphatidic acid
- PI phosphatidyl inositol
- one or more phospholipases are needed for the efficient removal of phospholipids from vegetable oils.
- WO2008094847A1 discloses a process for degumming an oil composition wherein the oil composition is contacted simultaneously with a phospholipase C and phospholipase A, resulting in an increased reduction of phosphorus as compared to the use of either of the enzymes alone.
- WO201 1/046815 discloses the use of a combination of PLC (with high affinity for PC and PE) and phosphatidyl-inositol-specific PLC (PI-PLC) to obtain efficient phospholipid hydrolysis in an enzymatic oil degumming process.
- PLC phosphatidyl-inositol-specific PLC
- WO2012/062817 discloses a phospholipase C enzyme from a strain Kinochaeta sp., which has activity towards the major phospholipids PC, PE, PA and PI.
- the present invention relates to a polypeptide having phospholipase C activity, selected from the group consisting of
- polypeptide comprising a mature polypeptide sequence of SEQ ID NO: 2;
- polypeptide that has 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the mature polypeptide sequence of SEQ ID NO: 2;
- a predicted polypeptide sequence according to SEQ ID NO: 2 was found in a public database wherein the polypeptide sequence was annotated as a sphingomyelin phosphodiesterase. Surprisingly, it was found that a polypeptide having a mature sequence of SEQ ID NO: 2 has a phospholipase C activity.
- a polypeptide as disclosed herein having phospholipase C activity comprises activity towards all of the major phospholipids phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl serine and/or phosphatidic acid at a broad temperature range up to 80°C and at a broad pH range, such as between pH 3 and 9. Furthermore, it was found that a phospholipase C according to the present invention efficiently hydrolyses a phospholipid substrate.
- a phospholipase as disclosed herein hydrolyses at least 80% of a phospholipid substrate at a concentration of less than 50 mg phospholipase (active) enzyme protein per gram of phospholipid in 24 hours.
- phospholipase (active) enzyme protein per gram of phospholipid Preferably less than 40, 30, 20 or 10 mg phospholipase (active) enzyme protein per gram of phospholipid, or less than 1 mg/g phospholipid is required to hydrolyse at least 80% of phospholipid substrate in 24 hours.
- the present invention relates to a composition comprising a polypeptide as defined herein.
- the present invention relates to a nucleic acid encoding a polypeptide having phospholipase C activity, which has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the mature polypeptide encoding sequence of SEQ ID NO: 1 .
- a nucleic acid as disclosed herein may comprise or may be SEQ ID NO: 1.
- the present invention relates to an expression vector comprising a nucleic acid as defined herein operably linked to one or more control sequence(s) that direct expression of the polypeptide in a host cell.
- the present invention relates to a recombinant host cell comprising a nucleic acid or an expression vector as defined herein and a method for preparing a polypeptide having phospholipase C activity comprising cultivating a host cell as defined herein in a suitable fermentation medium, under conditions that allow expression of the polypeptide, and preparing the polypeptide.
- the present invention relates to a process for hydrolysing phospholipids comprising incubating the phospholipids with a polypeptide having phospholipase C activity, or with a composition comprising a polypeptide as disclosed herein, wherein the phospholipids are hydrolysed.
- the present invention relates to a process for degumming a vegetable oil comprising contacting a vegetable oil comprising one or more phospholipids with a polypeptide having phospholipase C activity as disclosed herein or a composition comprising a polypeptide having phospholipase C activity as disclosed herein, wherein the one or more phospholipids are hydrolysed into diacylglycerol and phosphate ester and / or phosphate, separating the phosphate ester and / or phosphate from the vegetable oil wherein a degummed vegetable oil is obtained
- complementary strand can be used interchangeably with the term "complement”.
- the complement of a nucleic acid strand can be the complement of a coding strand or the complement of a non-coding strand.
- the complement of a nucleic acid encoding a polypeptide refers to the complementary strand of the strand encoding the amino acid sequence or to any nucleic acid molecule containing the same.
- control sequence can be used interchangeably with the term "expression-regulating nucleic acid sequence”.
- the term as used herein refers to nucleic acid sequences necessary for and/or affecting the expression of an operably linked coding sequence in a particular host organism or in vitro. When two nucleic acid sequences are operably linked, they will usually be in the same orientation and also in the same reading frame. They will usually be essentially contiguous, although this may not be required.
- the expression-regulating nucleic acid sequences such as inter alia appropriate transcription initiation, termination, promoter, leader, signal peptide, propeptide, prepropeptide, or enhancer sequences; Shine-Dalgarno sequence, repressor or activator sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (e.g., ribosome binding sites); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion, can be any nucleic acid sequence showing activity in the host organism of choice and can be derived from genes encoding proteins, which are either endogenous or heterologous to a host cell.
- Each control sequence may be native or foreign to the nucleic acid sequence encoding the polypeptide.
- the control sequence may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the nucleic acid sequence encoding a polypeptide.
- Control sequences may be optimized to their specific purpose.
- endogenous refers to a nucleic acid or amino acid sequence naturally occurring in a host.
- expression includes any step involved in the production of the polypeptide including, but not limited to transcription, post transcriptional modification, translation, post-translational modification, and secretion.
- An "expression vector” comprises a polynucleotide coding for a polypeptide, operably linked to the appropriate control sequences (such as a promoter, and transcriptional and translational stop signals) for expression and/or translation in vitro, or in the host cell of the polynucleotide.
- the expression vector may be any vector (e.g., a plasmid or virus), which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the polynucleotide.
- the choice of the vector will typically depend on the compatibility of the vector with the cell into which the vector is to be introduced.
- the vectors may be linear or closed circular plasmids.
- the vector may be an autonomously replicating vector, i.e.
- a vector which exists as an extra-chromosomal entity, the replication of which is independent of chromosomal replication e.g., a plasmid, an extra-chromosomal element, a mini-chromosome, or an artificial chromosome.
- the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated.
- the integrative cloning vector may integrate at random or at a predetermined target locus in the chromosomes of the host cell.
- the vector system may be a single vector or plasmid or two or more vectors or plasmids, which together contain the total DNA to be introduced into the genome of the host cell, or a transposon.
- a "host cell” as defined herein is an organism suitable for genetic manipulation and one which may be cultured at cell densities useful for industrial production of a target product, such as a polypeptide according to the present invention.
- a host cell may be a host cell found in nature or a host cell derived from a parent host cell after genetic manipulation or classical mutagenesis.
- a host cell is a recombinant host cell.
- a host cell may be a prokaryotic, archaebacterial or eukaryotic host cell.
- a prokaryotic host cell may be, but is not limited to, a bacterial host cell.
- a eukaryotic host cell may be, but is not limited to, a yeast, a fungus, an amoeba, an algae, a plant, an animal, or an insect host cell.
- heterologous refers to nucleic acid or amino acid sequences not naturally occurring in a host cell. In other words, the nucleic acid or amino acid sequence is not identical to that naturally found in the host cell.
- hybridization means the pairing of substantially complementary strands of oligomeric compounds, such as nucleic acid compounds. Hybridization may be performed under low, medium or high stringency conditions. Low stringency hybridization conditions comprise hybridizing in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by two washes in 0.2X SSC, 0.1 % SDS at least at 50°C (the temperature of the washes can be increased to 55°C for low stringency conditions).
- SSC sodium chloride/sodium citrate
- Medium stringency hybridization conditions comprise hybridizing in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1 % SDS at 60°C, and high stringency hybridization conditions comprise hybridizing in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1 % SDS at 65°C.
- nucleic acid or polynucleotide sequence is defined herein as a nucleotide polymer comprising at least 5 nucleotide or nucleic acid units.
- a nucleotide or nucleic acid refers to RNA and DNA.
- the terms “nucleic acid” and “polynucleotide sequence” are used interchangeably herein.
- a “peptide” refers to a short chain of amino acid residues linked by a peptide (amide) bonds.
- the shortest peptide, a dipeptide, consists of 2 amino acids joined by a single peptide bond.
- polypeptide refers to a molecule comprising amino acid residues linked by peptide bonds and containing more than five amino acid residues.
- protein as used herein is synonymous with the term “polypeptide” and may also refer to two or more polypeptides. Thus, the terms “protein” and “polypeptide” can be used interchangeably.
- Polypeptides may optionally be modified (e.g., glycosylated, phosphorylated, acylated, farnesylated, prenylated, sulfonated, and the like) to add functionality. Polypeptides exhibiting activity in the presence of a specific substrate under certain conditions may be referred to as enzymes. It will be understood that, as a result of the degeneracy of the genetic code, a multitude of nucleotide sequences encoding a given polypeptide may be produced.
- isolated nucleic acid fragment is a nucleic acid fragment that is not naturally occurring as a fragment and would not be found in the natural state.
- isolated polypeptide as used herein means a polypeptide that is removed from at least one component, e.g. other polypeptide material, with which it is naturally associated.
- the isolated polypeptide may be free of any other impurities.
- the isolated polypeptide may be at least 50% pure, e.g., at least 60% pure, at least 70% pure, at least 75% pure, at least 80% pure, at least 85% pure, at least 80% pure, at least 90% pure, or at least 95% pure, 96%, 97%, 98%, 99%, 99.5%, 99.9% as determined by SDS-PAGE or any other analytical method suitable for this purpose and known to the person skilled in the art.
- An isolated polypeptide may be produced by a recombinant host cell.
- a "mature polypeptide” is defined herein as a polypeptide in its final form and is obtained after translation of a mRNA into polypeptide and post-translational modifications of said polypeptide.
- Post-translational modification include N-terminal processing, C-terminal truncation, glycosylation, phosphorylation and removal of leader sequences such as signal peptides, propeptides and/or prepropeptides by cleavage.
- a "mature polypeptide coding sequence” means a polynucleotide that encodes a mature polypeptide.
- nucleic acid construct is herein referred to as a nucleic acid molecule, either single-or double-stranded, which is isolated from a naturally occurring gene or which has been modified to contain segments of nucleic acid which are combined and juxtaposed in a manner which would not otherwise exist in nature.
- nucleic acid construct is synonymous with the term “expression cassette” when the nucleic acid construct contains all the control sequences required for expression of a coding sequence, wherein said control sequences are operably linked to said coding sequence.
- promoter is defined herein as a DNA sequence that binds RNA polymerase and directs the polymerase to the correct downstream transcriptional start site of a nucleic acid sequence to initiate transcription.
- recombinant when used in reference to a cell, nucleic acid, protein or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified.
- recombinant cells express genes that are not found within the native (non- recombinant) form of the cell or express native genes that are otherwise abnormally expressed, underexpressed or not expressed at all.
- the term “recombinant” is synonymous with “genetically modified” and "transgenic”.
- sequence identity or sequence homology are used interchangeable herein. For the purpose of this invention, it is defined here that in order to determine the percentage of sequence homology or sequence identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes. In order to optimize the alignment between the two sequences gaps may be introduced in any of the two sequences that are compared. Such alignment can be carried out over the full length of the sequences being compared. Alternatively, the alignment may be carried out over a shorter length, for example over about 20, about 50, about 100 or more nucleic acids/bases or amino acids.
- sequence identity is the percentage of identical matches between the two sequences over the reported aligned region.
- the percent sequence identity between two amino acid sequences or between two nucleotide sequences may be determined using the Needleman and Wunsch algorithm for the alignment of two sequences. (Needleman, S. B. and Wunsch, C. D. (1970) J. Mol. Biol. 48, 443-453). Both amino acid sequences and nucleotide sequences can be aligned by the algorithm.
- the Needleman-Wunsch algorithm has been implemented in the computer program NEEDLE.
- the NEEDLE program from the EMBOSS package was used (version 2.8.0 or higher, EMBOSS: The European Molecular Biology Open Software Suite (2000) Rice,P. LongdenJ.
- the percentage of sequence identity between a query sequence and a sequence of the invention is calculated as follows: Number of corresponding positions in the alignment showing an identical amino acid or identical nucleotide in both sequences divided by the total length of the alignment after subtraction of the total number of gaps in the alignment.
- the identity as defined herein can be obtained from NEEDLE by using the NOBRIEF option and is labeled in the output of the program as "longest-identity".
- the nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against public databases to, for example, identify other family members or related sequences.
- Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403—10.
- Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25(17): 3389-3402.
- the default parameters of the respective programs e.g., XBLAST and NBLAST
- polypeptides refers to a polypeptide preparation which contains at the most 50% by weight of other polypeptide material.
- the polypeptides disclosed herein are preferably in a substantially pure form.
- the polypeptides disclosed herein are in "essentially pure form", i.e. that the polypeptide preparation is essentially free of other polypeptide material.
- the polypeptide may also be essentially free of non-polypeptide material such as nucleic acids, lipids, media components, and the like.
- substantially pure polypeptide is synonymous with the terms “isolated polypeptide” and "polypeptide in isolated form”.
- polynucleotide refers to a polynucleotide preparation which contains at the most 50% by weight of other polynucleotide material.
- the polynucleotides disclosed herein are preferably in a substantially pure form.
- the polynucleotide disclosed herein are in "essentially pure form", i.e. that the polynucleotide preparation is essentially free of other polynucleotide material.
- the polynucleotide may also be essentially free of non-polynucleotide material such as polypeptides, lipids, media components, and the like.
- substantially pure polynucleotide is synonymous with the terms “isolated polynucleotide” and "polynucleotide in isolated form”.
- a "synthetic molecule”, such as a synthetic nucleic acid or a synthetic polypeptide is produced by in vitro chemical or enzymatic synthesis. It includes, but is not limited to, variant nucleic acids made with optimal codon usage for host organisms of choice.
- a synthetic nucleic acid may be optimized for codon use, preferably according to the methods described in WO2006/077258 and/or WO2008000632, which are herein incorporated by reference.
- WO2008/000632 addresses codon-pair optimization.
- Codon-pair optimization is a method wherein the nucleotide sequences encoding a polypeptide that have been modified with respect to their codon-usage, in particular the codon-pairs that are used, are optimized to obtain improved expression of the nucleotide sequence encoding the polypeptide and/or improved production of the encoded polypeptide.
- Codon pairs are defined as a set of two subsequent triplets (codons) in a coding sequence.
- variants can be used interchangeably. They can refer to either polypeptides or nucleic acids. Variants include substitutions, insertions, deletions, truncations, transversions, and/or inversions, at one or more locations relative to a reference sequence. Variants can be made for example by site-saturation mutagenesis, scanning mutagenesis, insertional mutagenesis, random mutagenesis, site-directed mutagenesis, and directed-evolution, as well as various other recombination approaches known to a skilled person in the art. Variant genes of nucleic acids may be synthesized artificially by known techniques in the art.
- Figure 1 Schematic representation of the vector pGBTOP16 used for cloning the phospholipase C gene.
- the present invention relates to a polypeptide having phospholipase C activity, selected from the group consisting of
- polypeptide comprising a mature polypeptide sequence of SEQ ID NO: 2;
- polypeptide that has least 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the mature polypeptide sequence of SEQ ID NO: 2;
- iii a polypeptide encoded by a nucleic acid that hybridizes under medium stringency, preferably under high stringency conditions to the complementary strand of the mature polypeptide coding sequence of SEQ ID NO:1 ;
- polypeptide encoded by a nucleic acid that has at least 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the mature polypeptide coding sequence of SEQ ID NO: 1 .
- a polypeptide as defined herein having phospholipase C activity comprises activity towards all of the phospholipids phosphatidyl choline (PC), phosphatidyl ethanolamine (PE), phosphatidyl inositol (PI) and phosphatidic acid (PA).
- PC phosphatidyl choline
- PE phosphatidyl ethanolamine
- PI phosphatidyl inositol
- PA phosphatidic acid
- a single phospholipase can be used to hydrolyse the major phospholipids instead of using a mixture of different phospholipases, such as phospholipase C, phosphatidyl- inositol specific (PI-PLC), or phospholipase A, which have activity on one or a selection of the major phospholipids PC, PE, PI or PA.
- phospholipase C phosphatidyl- inositol specific
- PI-PLC phosphatidyl- inositol specific
- PA phospholipase A
- a polypeptide as disclosed herein has a pH optimum of about 4.5 to 5.
- a pH optimum of a polypeptide having phospholipase C activity as disclosed herein may be determined by measuring phospholipase C activity in an aqueous solution comprising 100mM acetate, 1 % Triton X-100 and 1 mM ZnS0 4 with p- nitrophenyl phosphorylcholine (pNP-PC) as a substrate at 37°C.
- a polypeptide having phospholipase C activity as disclosed herein more efficiently degraded phospholipids such as phosphatidyl choline (PC), phosphatidyl ethanolamine (PE), phosphatidyl inositol (PI) and phosphatidic acid (PA) in a neutral environment than in a more acid environment in a high oil / low water composition.
- a high oil / low water composition comprises less than 10, 8, 6, or 4 wt% of water relative to oil.
- a polypeptide as disclosed herein may be an isolated, substantially pure, pure, recombinant, synthetic or variant polypeptide or a non-naturally occurring polypeptide.
- a polypeptide having phospholipase C activity according to the present invention is advantageously derived from a Hypocrea sp., eg. Hypocrea virens.
- the wording "derived” or “derivable” from, with respect to the origin of a polypeptide as disclosed herein, means that when carrying out a BLAST search with a polypeptide according to the present invention, the polypeptide according to the present invention may be derivable from a natural source, such as a microbial cell, of which an endogenous polypeptide shows the highest percentage homology or identity with the polypeptide as disclosed herein.
- a polypeptide of the invention having phospholipase C activity is not a native polypeptide of Hypocrea virens containing a native leader sequence.
- a polypeptide of the invention having phospholipase C activity is not the complete amino acid sequence of SEQ ID NO: 2.
- a polypeptide of the invention having phospholipase C activity is not the amino acid sequence consisting of amino acids 1 to 643 of SEQ ID NO: 2.
- a polypeptide having phospholipase C activity (EC 3.1 .4.3) as disclosed herein is an enzyme that may hydrolyze phospholipids into diacylglyceride (DAG) and a phosphate from phosphatidic acid (PA), or DAG and a phosphate ester (from PC, PE and PI).
- DAG diacylglyceride
- PA phosphatidic acid
- a polypeptide having phospholipase C activity according to the present invention has activity to the major phospholipids phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, and phosphatidic acid.
- a polypeptide having activity to the major phospholipids is that only one phospholipase enzyme may be needed to hydrolyze all phospholipids into diglyceride and phosphate or phosphate ester, such as in a vegetable oil degumming process for efficient removal of phospholipids.
- a phospholipase as disclosed herein may have phosphatase activity E.C. 3.1 .3.
- a phosphatase catalyzes the conversion of a phosphate ester, for instance the conversion of phosphate esters PC PE and PI into phosphate and choline, ethanol amine and inositol, respectively.
- a polypeptide of SEQ ID NO: 2 comprises a leader sequence for secretion of the polypeptide outside cell.
- a leader sequence in SEQ ID NO: 2 may comprise amino acids 1 to 15, or 1 to 16, or 1 to 17, or 1 to 18 or 1 to 19, wherein the methionine (M) at position 1 is counted as 1 .
- a mature polypeptide sequence of SEQ ID NO: 2 as disclosed herein may comprise the amino acids from position 16, 17, 18, 19, or 20 to position 638, 639, 640, 641 , 642 or 643 of SEQ ID NO: 2 wherein the methionine (M) at position 1 is counted as 1 .
- a mature polypeptide of SEQ ID NO: 2 may comprise the amino acids from position 19 to position 643 of SEQ ID NO : 2, or is amino acids 19 to 643 of SEQ ID NO: 2, wherein the methionine (M) at position 1 is counted as 1 .
- a polypeptide that has least 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the mature polypeptide sequence of SEQ ID NO: 2 may be a polypeptide that has at least 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to amino acids 19 to 643 of SEQ ID NO: 2.
- a polypeptide according to the present disclosure may advantageously be an isolated, substantially pure, pure, recombinant, synthetic or variant polypeptide of the polypeptide as defined herein.
- a polypeptide as disclosed herein may be purified. Purification of protein is known to a skilled person in the art, and may for instance comprise steps as separating proteins from cells or cell fractions, for instance by centrifugation, ammonium sulphate precipitation, ultracentrifugation, chromatography, or filtration, or ultrafiltration.
- the present disclosure relates to a composition comprising a polypeptide as disclosed herein.
- a composition as disclosed herein may comprise a carrier, an excipient, an auxiliary enzyme, or other compounds.
- a composition, or a formulation comprises a compound with which a polypeptide having phospholipase C activity may be formulated.
- An excipient as used herein is an inactive substance formulated alongside with a polypeptide as disclosed herein, for instance sucrose or lactose, glycerol, sorbitol or sodium chloride.
- a composition comprising a polypeptide as disclosed herein may be a liquid composition or a solid composition.
- a liquid composition, typically an aqueous solution usually comprises water.
- the composition When formulated as a liquid composition, the composition usually comprises components that lower the water activity, such as glycerol, sorbitol or sodium chloride (NaCI).
- a solid composition comprising a polypeptide as disclosed herein may comprise a granulate comprising the enzyme or the composition comprises an encapsulated polypeptide in liquid matrices like liposomes or gels like alginate or carrageenans, or (synthetic. resins or silicas).
- a polypeptide or enzyme see for instance G.M.H. Meesters, "Encapsulation of Enzymes and Peptides", Chapter 9, in N.J. Zuidam and V.A. Nedovic (eds.) "Encapsulation Technologies for Active Food Ingredients and food processing” 2010).
- a composition as disclosed herein may also comprise a carrier comprising a polypeptide as disclosed herein.
- a polypeptide as disclosed herein may be bound or immobilized to a carrier by known technologies in the art, for instance by immobilizing the polypeptide on a carrier such as alginate or carrageenan.
- a composition as disclosed herein may also comprise an auxiliary enzyme, for instance a phospholipase A, or a PI-PLC.
- a composition as disclosed herein may comprise other enzymes that may be beneficial to enzyme assisted oil-degumming or refining.
- composition as disclosed herein may comprise one or more further enzyme(s) such as proteases, a chlorophyllases, pheophytinases, carbohydrases, for instance cell wall degrading enzymes such as cellulases, hemicellulases, pectinases and/ or ⁇ -glucosidases, and / or lipases.
- further enzyme(s) such as proteases, a chlorophyllases, pheophytinases, carbohydrases, for instance cell wall degrading enzymes such as cellulases, hemicellulases, pectinases and/ or ⁇ -glucosidases, and / or lipases.
- a composition comprising a polypeptide having phospholipase C activity as disclosed herein may also be a fermentation broth comprising the polypeptide.
- a composition may comprise a polypeptide having phospholipase C activity wherein the polypeptide is bound to cells or cell material. Alternatively, cells or cell material have been removed from the fermentation broth by centrifugation. Optionally, cells are killed for instance by a heating step.
- the present invention also relates to a process for preparing a composition comprising a polypeptide as disclosed herein, which may comprise spray drying a fermentation medium comprising the polypeptide, or granulating, or encapsulating a polypeptide as disclosed herein, and preparing the composition.
- Spray drying is known to a skilled person and usually comprises producing a dry powder from a liquid or slurry comprising a polypeptide as disclosed herein by rapidly drying with hot gas.
- the present invention relates to a nucleic acid encoding a polypeptide having phospholipase C activity as disclosed herein, which has at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 1 or to the mature polypeptide encoding sequence of SEQ ID NO: 1 .
- a nucleic acid of the present disclosure may be an isolated, substantially pure, pure, recombinant, synthetic or variant nucleic acid of the nucleic acid or a non- naturally occurring nucleic acid.
- a polynucleotide sequence as disclosed herein may comprise SEQ ID NO: 1 , or may comprise the mature polypeptide encoding sequence of SEQ ID NO:1 .
- nucleic acid is disclosed that is an isolated, substantially pure, pure, recombinant, synthetic or variant nucleic acid of the nucleic acid of SEQ ID NO: 1 .
- a variant nucleic acid sequence may for instance have at least 80% sequence identity to SEQ ID NO:1.
- the present invention relates to an expression vector comprising a nucleic acid as disclosed herein operably linked to one or more control sequence(s) that direct expression of the polypeptide in an expression host cell.
- An expression vector may be obtained for instance by inserting a nucleic acid of the present invention into an empty construct or vector.
- a nucleic acid construct or an expression vector There are several ways of inserting a nucleic acid into a nucleic acid construct or an expression vector which are known to a skilled person in the art, see for instance Sambrook & Russell, Molecular Cloning: A Laboratory Manual, 3rd Ed., CSHL Press, Cold Spring Harbor, NY, 2001 . It may be desirable to manipulate a nucleic acid encoding a polypeptide of the present invention with suitable control sequences.
- the one or more control sequence(s) in an expression vector as disclosed herein may comprise a promoter sequence, a terminator sequence, and / or a leader sequence. .
- a promoter may be any appropriate promoter sequence suitable for a eukaryotic or prokaryotic host cell, which shows transcriptional activity, including mutant, truncated, and hybrid promoters, and may be obtained from polynucleotides encoding extracellular or intracellular polypeptides either endogenous (native) or heterologous (foreign) to the cell.
- the promoter may be a constitutive or inducible promoter.
- the promoter is an inducible promoter, for instance a starch inducible promoter.
- Promoters suitable in filamentous fungi are promoters which may be selected from the group, which includes but is not limited to promoters obtained from the polynucleotides encoding A.
- oryzae TAKA amylase Rhizomucor miehei aspartic proteinase, Aspergillus gpdA promoter, A. niger neutral alpha-amylase, A. niger acid stable alpha-amylase, A. niger or A. awamori glucoamylase (glaA), A. niger or A. awamori endoxylanase (xlnA) or beta-xylosidase (x/nD), T reesei cellobiohydrolase I (CBHI), R. miehei lipase, A. oryzae alkaline protease, A. oryzae triose phosphate isomerase, A.
- Trichoderma reesei beta-glucosidase Trichoderma reesei cellobiohydrolase I, Trichoderma reesei cellobiohydrolase II, Trichoderma reesei endoglucanase I, Trichoderma reesei endoglucanase II, Trichoderma reesei endoglucanase III, Trichoderma reesei endoglucanase IV, Trichoderma reesei endoglucanase V, Trichoderma reesese
- any terminator which is functional in a cell as disclosed herein may be used, which are known to a skilled person in the art.
- suitable terminator sequences in filamentous fungi include terminator sequences of a filamentous fungal gene, such as from Aspergillus genes, for instance from the gene A. oryzae TAKA amylase, the genes encoding A. niger glucoamylase (glaA), A. nidulans anthranilate synthase, A. niger alpha-glucosidase, trpC and/or Fusarium oxysporum trypsin-like protease.
- Aspergillus genes for instance from the gene A. oryzae TAKA amylase
- glaA A. nidulans anthranilate synthase
- A. niger alpha-glucosidase trpC and/or Fusarium oxysporum trypsin-like protease
- the present invention relates to a recombinant host cell comprising a nucleic acid or an expression vector as disclosed herein.
- a suitable host cell may be a mammalian, insect, plant, fungal, or algal cell, or a bacterial cell.
- a suitable bacterial cell may be from the genera Bacillus, Streptomyces or Pseudomonas, for instance from the species B. amyloliquefaciens, B. licheformis, S. coeli color, or P. putida.
- a suitable host cell may be a fungal cell, for instance from the genus Acremonium, Aspergillus, Chrysosporium, Fusarium, Myceliophthora, Penicillium, Rasamsonia, Talaromyces, Thielavia, Trichoderma, Saccharomyces, Kluyveromyces, Pichia, for instance Aspergillus niger, Aspergillus awamori, Aspergillus foetidus, A. oryzae, A.
- a recombinant or transgenic host cell for expression of a phospholipase C as disclosed herein is an Aspergillus niger.
- the host cell may be genetically modified with a nucleic acid construct or expression vector as disclosed herein with standard techniques known in the art, such as electroporation, protoplast transformation or conjugation for instance as disclosed in Sambrook & Russell, Molecular Cloning: A Laboratory Manual, 3rd Ed., CSHL Press, Cold Spring Harbor, NY, 2001 .
- the present invention relates to a process for the production of a polypeptide as disclosed herein comprising cultivating a recombinant host cell as disclosed herein in a suitable fermentation medium under conditions conducive to the production of the polypeptide and producing the polypeptide.
- a suitable fermentation medium usually comprises nutrients such a nitrogen, a carbon source and other essential elements known to a skilled person in the art for cultivating a particular host cell.
- Host cells can be cultivated in shake flasks, or in fermenters having a volume of 0.5 or 1 litre or larger to 10 to 100 or more cubic metres. Cultivation may be performed aerobically or anaerobically depending on the requirements of a host cell.
- a process for preparing a polypeptide as disclosed herein may further comprise recovering the polypeptide from the fermentation medium.
- Recovering the polypeptide may comprise isolating the polypeptide.
- Recovering may be performed by known methods in the art for instance recovering may comprise filtration, ultrafiltration, microfiltration, centrifugation or chromatography.
- the present invention relates to a process for hydrolysing phospholipids comprising incubating the phospholipids with a polypeptide having phospholipase C activity as disclosed herein or a composition as disclosed herein, wherein the phospholipids are hydrolysed.
- Phospholipids that may be hydrolysed include phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidic acid, and/or phosphatidyl serine.
- Phospholipids may be derived from a vegetable oil or a fat, for instance an animal derived fat such a dairy fat.
- a process for hydrolysing phospholipids may comprise a step wherein phospholipids are separated from an oil, for instance a vegetable oil, or from a fat, for instance a dairy fat, for instance by water degumming, resulting in phospholipid- containing gums and water-degummed oil; incubating the phospholipid-containing gums with a polypeptide having phospholipase C activity as disclosed herein, wherein phospholipids are hydrolysed.
- a neutral oil fraction is usually obtained upon hydrolysis of the phospholipids and can be separated from the phosphor-containing fraction. The neutral oil can be then be added to the water degummed oil, which increases the yield of the oil.
- Incubating phospholipids with a polypeptide having phospholipase C activity may be performed at any suitable pH and temperature.
- a suitable pH may for instance be a pH of between 3 and 9, or a pH of between 4 and 8, or a pH of between 5 and 7, or a pH of between 6 and 8.
- a suitable temperature may be a temperature of between 20 and 80 °C, for instance between 30 and 70°C, such as between 40 and 60 °C or between 45 and 55 °C.
- the present invention relates to a process for degumming a vegetable oil comprising contacting a vegetable oil comprising one or more phospholipids with a polypeptide having phospholipase C activity as disclosed herein or a composition as disclosed herein, wherein the one or more phospholipids are hydrolysed into diacylglycerol and phosphate ester and / or phosphate, separating the phosphate ester and / or phosphate from the vegetable oil wherein a degummed vegetable oil is obtained.
- hydrolysing phospholipids means that at least part of the phospholipids is hydrolysed.
- phosphatidyl choline phosphatidyl ethanolamine
- phosphatidyl inositol phosphatidic acid and / or phosphatidyl serine is hydrolysed.
- Degumming a vegetable oil in a process as disclosed herein comprises reducing the phosphorus content in the vegetable oil.
- the atomic phosphorus content is reduced to less than 50 ppm P, or less than 20 ppm P or less than 10, or less than 5 ppm P, or less than 2 ppm P.
- the phosphorus content can be measured by standard ICP methods (inductively coupled plasma).
- a vegetable oil in a process according to the present disclosure may be a crude oil or a previously degummed oil by other means, for instance by water degumming.
- a vegetable oil may also be obtained by pressing oil seed (pressed oil or expeller), by hexane extraction of oil seed.
- a vegetable oil may for instance be canola oil, castor oil, coconut oil, corn oil, cotton oil palm oil, palm kernel oil, peanut oil, rapeseed oil, rice bran oil, soybean oil or sunflower oil.
- a process for degumming a vegetable oil as disclosed herein may further comprise a step of separating the degummed vegetable oil from gums. Such separating may for instance be achieved by centrifugation.
- a polypeptide having phospholipase C activity may be dissolved in an aqueous medium and brought into contact with the vegetable oil by mixing or stirring, for instance by high-shear mixing.
- a process for degumming a vegetable oil may be carried out at a pH of between 3 and 9, or a pH between 4 and 8, or a pH between 5 and 7, or a pH between 4 and 6, or a pH of between 3 and 7.
- the pH can be adjusted by known methods in the art for instance by the addition of acids, such as citric or phosphoric acid, optionally subsequently or simultaneously adding caustic such as sodium hydroxide.
- acids such as citric or phosphoric acid
- caustic such as sodium hydroxide.
- phospholipids are hydrolysed at an acid pH value, since when phospholipids are hydrated they are more easily hydrolysed.
- the temperature at which a process for degumming is carried out may be between 20 and 90 °C, or between 25 and 80 °C, such as between 30 and 70 °C, or between 40 and 60 °C, for instance between 45 and 55 °C, for instance at a temperature of between 50 and 90 °C. It was found advantageous to carry out a process for degumming at an elevated temperature, because the removal of gums rich in phosphorous-containing compounds by centrifugation is mostly done at elevated temperatures, such as 80°C. If the enzyme-assisted hydrolysis of phospholipids is performed at elevated temperature such as between 70 and 90 °C, the temperature of the oil does not need to be lowered after hexane extraction or pressing and before enzyme-assisted hydrolysis.
- the present invention relates to a degummed vegetable oil obtainable by a process as disclosed herein.
- a polypeptide of Hypocrea virens of SEQ ID NO: 2, (L061 sequence) comprises a signal sequence of 18 amino acids for efficient secretion in Hypocrea virens, and a deduced mature protein sequence of 625 amino acids.
- a codon-adapted DNA sequence for expression of the protein in Aspergillus niger was designed containing additional restriction sites for subcloning in an Aspergillus expression vector. Codon adaptation was performed as described in WO2008/000632. The codon optimized DNA sequence for expression of the gene encoding the L061 protein of SEQ ID NO: 2 in A. niger is shown in SEQ ID NO: 1 .
- the translational initiation sequence of the glucoamylase glaA promoter was modified into 5'-CACCGTCAAA ATG-3' (SEQ ID NO:3) and an optimal translational termination sequence 5'-TAAA-3' was used in the generation of the expression constructs (as also detailed in WO2006/077258).
- the pGBTOP-16 vector ( Figure 1 ) was linearized by EcoR ⁇ /Pac ⁇ digestion and the linearized vector fragment was subsequently purified by gel-extraction. The DNA fragments were cloned into the pGBTOP-16 vector and the resulting vector was named pGBTOPL061 . Subsequently, A. niger GBA 306 was transformed with pGBTOPL061 in a co-transformation protocol with pGBAAS-4, with strain and methods as described in WO 201 1/009700 and references therein, and selected on acetamide containing media and colony purified according to standard procedures. Transformation and selection was performed as described in WO 98/46772 and WO 99/32617.
- Strains containing the L061 gene were selected via PCR with primers amplifying the introduced L061 gene to verify presence of the pGBTOPL061 expression cassette. A single transformant expressing NBL-L061 was selected, and further replica-plated to obtain a single strain inoculum.
- Fresh A. niger NBL-L061 spores were prepared and used for generating sample material by cultivation of the strain in 24 deep well plates (Axygen, Union City, USA) containing 3 ml fermentation medium 2 (15 % w/v maltose, 6 % w/v bacto-soytone, 1 .5 % w/v (NH 4 ) 2 S0 4 , 0.1 % w/v NaH 2 P0 4 .H 2 0, 0.1 % w/v MgS0 4 .7H 2 0, 0.1 % w/v L- arginine, 8 %o w/v Tween-80, 2 %o w/v Basildon, 2 % w/v MES, pH 5.1 ).
- the 24 deep well plates were covered with a Breathseal (Greiner bio-one, Frickenhausen, Germany) and a lid. After 6 days of growth at 34 ° C, 550 rpm and 80% humidity in a Microton incubator shaker (Infors AG, Bottmingen, Switzerland) 1 .5 mL samples were taken, the mycelium was separated from the supernatant by centrifugation for 30 min at 4000g and the supernatants were stored at -20°C until further analyses.
- PLC Phospholipase C
- the PLC activity of the samples L061 A5 and C5 was determined using the chromogenic substrate p-nitrophenyl phosphorylcholine (pNP-PC).
- the substrate solution consisted of 10 mM pNP-PC (Sigma N5879, Zwijndrecht, the Netherlands), 100mM acetate buffer
- Calibration was performed by preparing pNP solutions of respectively 0 - 0.5 - 1 .0 - 2.0 - 2.9 - 4.0 mM in above mentioned buffer. 20 ⁇ _ of each standard solution was mixed with 180 ⁇ _ substrate and 100 ⁇ _ of the mixture was added to 100 ⁇ _ stop reagent. The OD of each solution was measured at 405 nm. By using linear regression, the slope of the calibration line was calculated.
- One U is defined as the amount of enzyme that liberates 1 ⁇ p-nitrophenol per minute under the conditions of the test (pH 5, 37°C).
- PLC Phospholipase C
- the sample had been diluted in 100 mM acetate buffer pH 5.0 with 0.2% triton X-100 and 1 .0 mM Zinc sulfate. After centrifugation, the supernatant was used for the activity assay.
- the sample was diluted in such a way that the AAbs is between 0.1 and 1 .0. Accordingly, calibration was performed by preparing pNP solutions in 1000 ⁇ and incubation was performed for 30 min.
- Protein content was measured according the "Coomassie Plus protein kit" of Pierce (art. no. 23236).
- Table 1 Phospholipase C activity of different screening samples of Hypocrea virens gene codon optimized for and expressed in Aspergillus niger.
- Table 2 Phospholipase C activity of different samples of the Hypocrea virens gene codon optimized and expressed in Aspergillus niger.
- the pH profile of phospholipase L061 was determined in a solution of 10mM pNP-PC, 30 mM acetic acid, 30 mM MOPS, 30 mM MES, 0.2% triton X-100 and 1 mM ZnS0 4 adjusted with NaOH to a pH ranging from 4 to 7.5. Subsequently the same procedure as described in Example 3 was followed. A shake-flask-produced enzyme sample with an activity of 1 .0 U/mL was used.
- the temperature profile phospholipase L061 was determined using the method of Example 3 at different temperatures, using an enzyme sample prepared by a shake flask fermentation with an activity of 0.06 U/mL.
- Example 5 Hydrolysis of phospholipids in a dispersion of de-oiled lecithin in water at pH 5 and 6 and 60°C
- This dispersion was stirred at 37°C or 60°C for 24 hrs. After 4 and 24 hours a sample was taken. The sample was immediately heat treated to inactivate the enzyme by holding the sample for 5 minutes in a boiling water bath. Subsequently the samples were kept frozen until analysis by 31 P NMR.
- composition of phosphorous compounds was analyzed by 31 P NMR and diacylglyceride (DAG) levels by H PLC.
- TIP/TMP internal standard solution was prepared by mixing 100mM Triisopropyl phosphate (TI P, 97%, Aldrich, #554669) and Trimethylphosphate (TMP, 99+%, Aldrich, #241024) solutions in 2-propanol (I PA, HPLC grade, J.T. Baker, #9095-33) respectively, at a ratio of 1 : 1 .
- An extraction buffer was made with the same composition as the NMR solvent used for Example 5, except that the pH was brought to 10.5 using solid KOH.
- the extraction buffer was used to extract the phospholipids from the oil: An aliquot of -220 L of well stirred oil was weighed accurately into a 2 mL tube. 100 ⁇ D 2 0, and 900 ⁇ extracting buffer were added to the tube. The sample was mixed at room temperature and 1400rpm for 60 minutes (benchtop Eppendorf Thermomixer R). After 60 minutes, the sample was centrifuged in a benchtop Eppendorf 5417C centrifuge at 14000rpm for 10 minutes.
- aqueous extraction layer 600 ⁇ was transferred into a new tube, followed by accurate addition of 24 ⁇ of the TIP/TMP standard solution to the sample. The mixture was mixed using a benchtop vortex for 15 seconds. 500 ⁇ _ of this sample (accurately) was transferred into a clean NMR tube. NMR measurements were performed using a Bruker AVANCETM 500 MHz NMR with QNP 500MHz S2 5mm probe with Z-gradient, using the 31 P Channel at 202.4Hz and proton decoupling. The temperature was set at 300K. The number of scans was typically set at 512, and a relaxation delay at 0.1 s.
- Diacylglyceride levels were determined using a variant of the AOCS Official Method Cd 1 1 d-96 by H PLC-ELSD, using an Agilent 1260 HPLC system with Agilent 380 - ELSD and Agilent Prep-SIL Scalar HPLC column (4.6 x 150 mm, 10 ⁇ particle size; part# 443910-901 ).
- EMD Hexanes part# HX0290P-1 , EMD Ethyl Acetate, part# EX0245P-1 , EMD Isopropyl Alcohol (IPA), part# PX1838P-1 , EMD formic acid 98-100 %, part# 1 1 16701000, Sigma Aldrich 1 ,2-Dipalmitoyl-rac-glycerol, ⁇ 99%, part# D2135-1 G, Sigma Aldrich Glyceryl 1 ,3-dipalmitate, ⁇ 99%, part# D1639- 1 G.
- IPA Isopropyl Alcohol
- Table 8 1 ,2-diacylglyceride and 1 ,3 diacylglyceride level in soybean oil incubated with phospholipase L061 in wt% versus time
- Tables 9 and 10 show that the polypeptide having phospholipase according of the present disclosure had activity towards all phospholipids PA, PE, PI and PC present in crude soy bean oil under acid conditions.
- Table 1 1 shows that the 1 ,2 diacylglyceride production ran parallel with the breakdown of intact phospholipids.
- Table 9. Amount (in ⁇ ) of phospholipids, phosphate and phosphate esters in soybean oil incubated with phospholipase L061 versus time
- Example 6 and 7 show that a phospholipase of the present disclosure hydrolysed a higher amount of the phospholipids phosphatidyl choline, phosphatidyl ethanol amine, phosphatidyl inositol phosphatidic acid under neutral conditions than under acidic conditions.
- Example 8 Hydrolysis of phospholipids in rape seed oil
- Extracted rape seed oil from European origin 100 mL was pretreated with 200 ppm NaOH, and directly after that 5% w/w enzyme was added, that was obtained from a shake flask fermentation by treating broth with 10 mg Triton / gram broth, 60 min at room temperature and 10 minutes centrifugation at 4,000 rpm.
- the sample was sheared by a Silverson high shear mixer (1 minute at full speed) and left to incubate well stirred at 60°C for 24 hours. During incubation samples were drawn.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to a polypeptide having phospholipase C activity, selected from the group consisting of i. a polypeptide comprising a mature polypeptide sequence of SEQ ID NO: 2; ii. a polypeptide that has least 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the mature polypeptide sequence of SEQ ID NO: 2; iii. a polypeptide encoded by a nucleic acid that hybridizes under medium stringency, preferably under high stringency conditions to the complementary strand of the mature polypeptide coding sequence of SEQ ID NO:1; iv. a polypeptide encoded by a nucleic acid that has at least 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the mature polypeptide coding sequence of SEQ ID NO: 1. A process for degumming a vegetable oil comprising contacting a vegetable oil comprising phospholipids with a polypeptide having phospholipase C activity of the invention or a composition of the invention, wherein phospholipids are hydrolysed into diacylglycerol and phosphate ester and / or phosphate, separating the phosphate ester and/or phosphate from the vegetable oil wherein a degummed vegetable oil is obtained.
Description
PHOSPHOLIPASE C
The present invention relates to a polypeptide having phospholipase C activity and a process for degumming a vegetable oil.
Background
Phospholipases are a group of enzymes that catalyze the cleavage of phospholipids. There are several types of phospholipases. Phospholipase A1 (PLA1 ) removes the 1 -position fatty acid from the phospholipid to produce a free fatty acid and a 1 -lyso-2-acylphospholipid. Phospholipase B (PLB) hydrolyses both fatty acids leading to a glycerophosphate compound and two fatty acids, also known as lysophospholipase, and is considered an enzyme with a combination of both PLA1 and PLA2 activities. Phospholipase C (PLC) cleaves the glycerophosphate bond of phospholipids to produce a 1 ,2-diacylglycerol (DAG) and a phosphate or a phosphate ester (such as choline phosphate, ethanolamine phosphate and inositol phosphate). Phospholipase D (PLD) produces 1 ,2-diacylglycerophosphate, also known as phosphatidic acid, and a base group. Phospholipases are used amongst others in the refining or degumming of vegetable oils.
Traditionally, the degumming of vegetable oils is performed by hydrating the phospholipids in the oil by water, followed by separation of the phospholipids by for instance centrifugation. Alternatively also acid and/or caustic treatments may be used to optimize the separation. The removal of phospholipids causes substantial loss of oil during the refining of vegetable oils. The use of enzymatic treatment of phospholipids reduces the oil losses associated with traditional oil degumming methods. Phospholipase C (PLC) is in such separation particularly useful as it creates a diglyceride from the phospholipid, which adds to the neutral oil yield, and it breaks the emulsifying power of phospholipid, which results in less oil loss to the gum phase. Phospholipase A1 or A2, is compared to PLC less advantageous as it creates a lysophospholipid and a fatty acid. The latter still needs to be removed in an extra step further downstream in the refining process, and the lysophospholipid still has emulsifying power and will still absorb some neutral oil in the gum phase. Extended overviews of enzymatic oil degumming processes can be found in F. Galhardo and C. Dayton (2012), Enzymatic Degumming, in AOCS Lipid Library
(http://lipidlibrarv-aocs.orq/processinq/dequm-enz/index.htrri), and A. J. Dijkstra, 'Enzymatic degumming' in: Eur. J. Lipid Sci. Technol. 2010, 1 12, 1 178-1 189.
The major phospholipids in vegetable seed oils are phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidic acid (PA) and phosphatidyl inositol (PI). Depending on the affinity of phospholipases to any of the phospholipids, one or more phospholipases are needed for the efficient removal of phospholipids from vegetable oils.
WO2008094847A1 discloses a process for degumming an oil composition wherein the oil composition is contacted simultaneously with a phospholipase C and phospholipase A, resulting in an increased reduction of phosphorus as compared to the use of either of the enzymes alone.
WO201 1/046815 discloses the use of a combination of PLC (with high affinity for PC and PE) and phosphatidyl-inositol-specific PLC (PI-PLC) to obtain efficient phospholipid hydrolysis in an enzymatic oil degumming process.
WO2012/062817 discloses a phospholipase C enzyme from a strain Kinochaeta sp., which has activity towards the major phospholipids PC, PE, PA and PI.
An alternative phospholipase C which shows activity towards the phospholipids PC, PE, PA and PI from Penicillium emersonii is disclosed in WO2014/090161.
There is a need for a further phospholipase C enzyme which efficiently hydrolyses all major the phospholipids PC, PE, PA and PI
Summary
The present invention relates to a polypeptide having phospholipase C activity, selected from the group consisting of
i. a polypeptide comprising a mature polypeptide sequence of SEQ ID NO: 2;
ii. a polypeptide that has 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the mature polypeptide sequence of SEQ ID NO: 2;
iii. a polypeptide encoded by a nucleic acid that hybridizes under medium stringency, preferably under high stringency conditions to the complementary strand of the mature polypeptide coding sequence of SEQ ID NO:1 ;
iv. a polypeptide encoded by a nucleic acid that has at least 80%, 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the mature polypeptide coding sequence of SEQ ID NO: 1 .
A predicted polypeptide sequence according to SEQ ID NO: 2 was found in a public database wherein the polypeptide sequence was annotated as a sphingomyelin phosphodiesterase. Surprisingly, it was found that a polypeptide having a mature sequence of SEQ ID NO: 2 has a phospholipase C activity. Surprisingly, a polypeptide as disclosed herein having phospholipase C activity comprises activity towards all of the major phospholipids phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl serine and/or phosphatidic acid at a broad temperature range up to 80°C and at a broad pH range, such as between pH 3 and 9. Furthermore, it was found that a phospholipase C according to the present invention efficiently hydrolyses a phospholipid substrate. For instance, a phospholipase as disclosed herein hydrolyses at least 80% of a phospholipid substrate at a concentration of less than 50 mg phospholipase (active) enzyme protein per gram of phospholipid in 24 hours. Preferably less than 40, 30, 20 or 10 mg phospholipase (active) enzyme protein per gram of phospholipid, or less than 1 mg/g phospholipid is required to hydrolyse at least 80% of phospholipid substrate in 24 hours. These characteristics are advantageous in oil degumming processes.
In one aspect the present invention relates to a composition comprising a polypeptide as defined herein.
In another aspect the present invention relates to a nucleic acid encoding a polypeptide having phospholipase C activity, which has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the mature polypeptide encoding sequence of SEQ ID NO: 1 . A nucleic acid as disclosed herein may comprise or may be SEQ ID NO: 1.
In yet another aspect the present invention relates to an expression vector comprising a nucleic acid as defined herein operably linked to one or more control sequence(s) that direct expression of the polypeptide in a host cell.
In other aspects the present invention relates to a recombinant host cell comprising a nucleic acid or an expression vector as defined herein and a method for preparing a polypeptide having phospholipase C activity comprising cultivating a host
cell as defined herein in a suitable fermentation medium, under conditions that allow expression of the polypeptide, and preparing the polypeptide.
In yet another aspect the present invention relates to a process for hydrolysing phospholipids comprising incubating the phospholipids with a polypeptide having phospholipase C activity, or with a composition comprising a polypeptide as disclosed herein, wherein the phospholipids are hydrolysed.
In another aspect the present invention relates to a process for degumming a vegetable oil comprising contacting a vegetable oil comprising one or more phospholipids with a polypeptide having phospholipase C activity as disclosed herein or a composition comprising a polypeptide having phospholipase C activity as disclosed herein, wherein the one or more phospholipids are hydrolysed into diacylglycerol and phosphate ester and / or phosphate, separating the phosphate ester and / or phosphate from the vegetable oil wherein a degummed vegetable oil is obtained
Definitions
The term "complementary strand" can be used interchangeably with the term "complement". The complement of a nucleic acid strand can be the complement of a coding strand or the complement of a non-coding strand. When referring to double- stranded nucleic acids, the complement of a nucleic acid encoding a polypeptide refers to the complementary strand of the strand encoding the amino acid sequence or to any nucleic acid molecule containing the same.
The term "control sequence" can be used interchangeably with the term "expression-regulating nucleic acid sequence". The term as used herein refers to nucleic acid sequences necessary for and/or affecting the expression of an operably linked coding sequence in a particular host organism or in vitro. When two nucleic acid sequences are operably linked, they will usually be in the same orientation and also in the same reading frame. They will usually be essentially contiguous, although this may not be required. The expression-regulating nucleic acid sequences, such as inter alia appropriate transcription initiation, termination, promoter, leader, signal peptide, propeptide, prepropeptide, or enhancer sequences; Shine-Dalgarno sequence, repressor or activator sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (e.g., ribosome binding sites); sequences that
enhance protein stability; and when desired, sequences that enhance protein secretion, can be any nucleic acid sequence showing activity in the host organism of choice and can be derived from genes encoding proteins, which are either endogenous or heterologous to a host cell. Each control sequence may be native or foreign to the nucleic acid sequence encoding the polypeptide. When desired, the control sequence may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the nucleic acid sequence encoding a polypeptide. Control sequences may be optimized to their specific purpose.
As used herein, the term "endogenous" refers to a nucleic acid or amino acid sequence naturally occurring in a host.
The term "expression" includes any step involved in the production of the polypeptide including, but not limited to transcription, post transcriptional modification, translation, post-translational modification, and secretion.
An "expression vector" comprises a polynucleotide coding for a polypeptide, operably linked to the appropriate control sequences (such as a promoter, and transcriptional and translational stop signals) for expression and/or translation in vitro, or in the host cell of the polynucleotide. The expression vector may be any vector (e.g., a plasmid or virus), which can be conveniently subjected to recombinant DNA procedures and can bring about the expression of the polynucleotide. The choice of the vector will typically depend on the compatibility of the vector with the cell into which the vector is to be introduced. The vectors may be linear or closed circular plasmids. The vector may be an autonomously replicating vector, i.e. a vector which exists as an extra-chromosomal entity, the replication of which is independent of chromosomal replication, e.g., a plasmid, an extra-chromosomal element, a mini-chromosome, or an artificial chromosome. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. The integrative cloning vector may integrate at random or at a predetermined target locus in the chromosomes of the host cell. The vector system may be a single vector or plasmid or two or more vectors or plasmids, which together contain the total DNA to be introduced into the genome of the host cell, or a transposon.
A "host cell" as defined herein is an organism suitable for genetic manipulation and one which may be cultured at cell densities useful for industrial production of a target product, such as a polypeptide according to the present invention. A host cell may be a host cell found in nature or a host cell derived from a parent host cell after genetic manipulation or classical mutagenesis. Advantageously, a host cell is a recombinant host cell. A host cell may be a prokaryotic, archaebacterial or eukaryotic host cell. A prokaryotic host cell may be, but is not limited to, a bacterial host cell. A eukaryotic host cell may be, but is not limited to, a yeast, a fungus, an amoeba, an algae, a plant, an animal, or an insect host cell.
The term "heterologous" as used herein refers to nucleic acid or amino acid sequences not naturally occurring in a host cell. In other words, the nucleic acid or amino acid sequence is not identical to that naturally found in the host cell.
The term "hybridization" means the pairing of substantially complementary strands of oligomeric compounds, such as nucleic acid compounds. Hybridization may be performed under low, medium or high stringency conditions. Low stringency hybridization conditions comprise hybridizing in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by two washes in 0.2X SSC, 0.1 % SDS at least at 50°C (the temperature of the washes can be increased to 55°C for low stringency conditions). Medium stringency hybridization conditions comprise hybridizing in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1 % SDS at 60°C, and high stringency hybridization conditions comprise hybridizing in 6X SSC at about 45°C, followed by one or more washes in 0.2X SSC, 0.1 % SDS at 65°C.
A "nucleic acid or polynucleotide sequence" is defined herein as a nucleotide polymer comprising at least 5 nucleotide or nucleic acid units. A nucleotide or nucleic acid refers to RNA and DNA. The terms "nucleic acid" and "polynucleotide sequence" are used interchangeably herein.
A "peptide" refers to a short chain of amino acid residues linked by a peptide (amide) bonds. The shortest peptide, a dipeptide, consists of 2 amino acids joined by a single peptide bond.
The term "polypeptide" refers to a molecule comprising amino acid residues linked by peptide bonds and containing more than five amino acid residues. The term "protein" as used herein is synonymous with the term "polypeptide" and may also refer to two or more polypeptides. Thus, the terms "protein" and "polypeptide" can be used
interchangeably. Polypeptides may optionally be modified (e.g., glycosylated, phosphorylated, acylated, farnesylated, prenylated, sulfonated, and the like) to add functionality. Polypeptides exhibiting activity in the presence of a specific substrate under certain conditions may be referred to as enzymes. It will be understood that, as a result of the degeneracy of the genetic code, a multitude of nucleotide sequences encoding a given polypeptide may be produced.
An "isolated nucleic acid fragment" is a nucleic acid fragment that is not naturally occurring as a fragment and would not be found in the natural state.
The term "isolated polypeptide" as used herein means a polypeptide that is removed from at least one component, e.g. other polypeptide material, with which it is naturally associated. The isolated polypeptide may be free of any other impurities. The isolated polypeptide may be at least 50% pure, e.g., at least 60% pure, at least 70% pure, at least 75% pure, at least 80% pure, at least 85% pure, at least 80% pure, at least 90% pure, or at least 95% pure, 96%, 97%, 98%, 99%, 99.5%, 99.9% as determined by SDS-PAGE or any other analytical method suitable for this purpose and known to the person skilled in the art. An isolated polypeptide may be produced by a recombinant host cell.
A "mature polypeptide" is defined herein as a polypeptide in its final form and is obtained after translation of a mRNA into polypeptide and post-translational modifications of said polypeptide. Post-translational modification include N-terminal processing, C-terminal truncation, glycosylation, phosphorylation and removal of leader sequences such as signal peptides, propeptides and/or prepropeptides by cleavage.
A "mature polypeptide coding sequence" means a polynucleotide that encodes a mature polypeptide.
The term "nucleic acid construct" is herein referred to as a nucleic acid molecule, either single-or double-stranded, which is isolated from a naturally occurring gene or which has been modified to contain segments of nucleic acid which are combined and juxtaposed in a manner which would not otherwise exist in nature. The term nucleic acid construct is synonymous with the term "expression cassette" when the nucleic acid construct contains all the control sequences required for expression of a coding sequence, wherein said control sequences are operably linked to said coding sequence.
The term "promoter" is defined herein as a DNA sequence that binds RNA polymerase and directs the polymerase to the correct downstream transcriptional start site of a nucleic acid sequence to initiate transcription.
The term "recombinant" when used in reference to a cell, nucleic acid, protein or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found within the native (non- recombinant) form of the cell or express native genes that are otherwise abnormally expressed, underexpressed or not expressed at all. The term "recombinant" is synonymous with "genetically modified" and "transgenic".
"Sequence identity", or sequence homology are used interchangeable herein. For the purpose of this invention, it is defined here that in order to determine the percentage of sequence homology or sequence identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes. In order to optimize the alignment between the two sequences gaps may be introduced in any of the two sequences that are compared. Such alignment can be carried out over the full length of the sequences being compared. Alternatively, the alignment may be carried out over a shorter length, for example over about 20, about 50, about 100 or more nucleic acids/bases or amino acids. The sequence identity is the percentage of identical matches between the two sequences over the reported aligned region. The percent sequence identity between two amino acid sequences or between two nucleotide sequences may be determined using the Needleman and Wunsch algorithm for the alignment of two sequences. (Needleman, S. B. and Wunsch, C. D. (1970) J. Mol. Biol. 48, 443-453). Both amino acid sequences and nucleotide sequences can be aligned by the algorithm. The Needleman-Wunsch algorithm has been implemented in the computer program NEEDLE. For the purpose of this invention the NEEDLE program from the EMBOSS package was used (version 2.8.0 or higher, EMBOSS: The European Molecular Biology Open Software Suite (2000) Rice,P. LongdenJ. and BleasbyA Trends in Genetics 16, (6) pp276— 277, http://emboss.bioinformatics.nl/). For protein sequences EBLOSUM62 is used for the substitution matrix. For nucleotide sequence, EDNAFULL is used. The optional parameters used are Needleman_Wunsch settings: Score*1 , Matrix: BLOSUM62, a gap-open penalty of 10 and a gap extension penalty of 0.5. The skilled person will
appreciate that all these different parameters will yield slightly different results but that the overall percentage identity of two sequences is not significantly altered when using different algorithms.
After alignment by the program NEEDLE as described above the percentage of sequence identity between a query sequence and a sequence of the invention is calculated as follows: Number of corresponding positions in the alignment showing an identical amino acid or identical nucleotide in both sequences divided by the total length of the alignment after subtraction of the total number of gaps in the alignment. The identity as defined herein can be obtained from NEEDLE by using the NOBRIEF option and is labeled in the output of the program as "longest-identity".
The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using the NBLAST and XBLAST programs (version 2.0) of Altschul, et al. (1990) J. Mol. Biol. 215:403—10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, word length = 12 to obtain nucleotide sequences homologous to nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., (1997) Nucleic Acids Res. 25(17): 3389-3402. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used. See the homepage of the National Center for Biotechnology Information at http://www.ncbi.nlm.nih.gov/.
The term "substantially pure" with regard to polypeptides refers to a polypeptide preparation which contains at the most 50% by weight of other polypeptide material. The polypeptides disclosed herein are preferably in a substantially pure form. In particular, it is preferred that the polypeptides disclosed herein are in "essentially pure form", i.e. that the polypeptide preparation is essentially free of other polypeptide material. Optionally, the polypeptide may also be essentially free of non-polypeptide material such as nucleic acids, lipids, media components, and the like. Herein, the term "substantially pure polypeptide" is synonymous with the terms "isolated polypeptide" and "polypeptide in isolated form". The term "substantially pure" with regard to
polynucleotide refers to a polynucleotide preparation which contains at the most 50% by weight of other polynucleotide material. The polynucleotides disclosed herein are preferably in a substantially pure form. In particular, it is preferred that the polynucleotide disclosed herein are in "essentially pure form", i.e. that the polynucleotide preparation is essentially free of other polynucleotide material. Optionally, the polynucleotide may also be essentially free of non-polynucleotide material such as polypeptides, lipids, media components, and the like. Herein, the term "substantially pure polynucleotide" is synonymous with the terms "isolated polynucleotide" and "polynucleotide in isolated form".
A "synthetic molecule", such as a synthetic nucleic acid or a synthetic polypeptide is produced by in vitro chemical or enzymatic synthesis. It includes, but is not limited to, variant nucleic acids made with optimal codon usage for host organisms of choice.
A synthetic nucleic acid may be optimized for codon use, preferably according to the methods described in WO2006/077258 and/or WO2008000632, which are herein incorporated by reference. WO2008/000632 addresses codon-pair optimization. Codon-pair optimization is a method wherein the nucleotide sequences encoding a polypeptide that have been modified with respect to their codon-usage, in particular the codon-pairs that are used, are optimized to obtain improved expression of the nucleotide sequence encoding the polypeptide and/or improved production of the encoded polypeptide. Codon pairs are defined as a set of two subsequent triplets (codons) in a coding sequence. Those skilled in the art will know that the codon usage needs to be adapted depending on the host species, possibly resulting in variants with significant homology deviation from SEQ ID NO: 1 , but still encoding the polypeptide according to the invention.
As used herein, the terms "variant", "derivative", "mutant" or "homologue" can be used interchangeably. They can refer to either polypeptides or nucleic acids. Variants include substitutions, insertions, deletions, truncations, transversions, and/or inversions, at one or more locations relative to a reference sequence. Variants can be made for example by site-saturation mutagenesis, scanning mutagenesis, insertional mutagenesis, random mutagenesis, site-directed mutagenesis, and directed-evolution, as well as various other recombination approaches known to a skilled person in the art.
Variant genes of nucleic acids may be synthesized artificially by known techniques in the art.
FIGURES
Figure 1 : Schematic representation of the vector pGBTOP16 used for cloning the phospholipase C gene.
Detailed description
The present invention relates to a polypeptide having phospholipase C activity, selected from the group consisting of
i. a polypeptide comprising a mature polypeptide sequence of SEQ ID NO: 2;
ii. a polypeptide that has least 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the mature polypeptide sequence of SEQ ID NO: 2;
iii. a polypeptide encoded by a nucleic acid that hybridizes under medium stringency, preferably under high stringency conditions to the complementary strand of the mature polypeptide coding sequence of SEQ ID NO:1 ;
iv. a polypeptide encoded by a nucleic acid that has at least 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the mature polypeptide coding sequence of SEQ ID NO: 1 .
Surprisingly, it was found that a polypeptide as defined herein having phospholipase C activity comprises activity towards all of the phospholipids phosphatidyl choline (PC), phosphatidyl ethanolamine (PE), phosphatidyl inositol (PI) and phosphatidic acid (PA). It is advantageous in oil degumming processes that a single phospholipase can be used to hydrolyse the major phospholipids instead of using a mixture of different phospholipases, such as phospholipase C, phosphatidyl- inositol specific (PI-PLC), or phospholipase A, which have activity on one or a selection of the major phospholipids PC, PE, PI or PA.
A polypeptide as disclosed herein has a pH optimum of about 4.5 to 5. For instance a pH optimum of a polypeptide having phospholipase C activity as disclosed herein may be determined by measuring phospholipase C activity in an aqueous
solution comprising 100mM acetate, 1 % Triton X-100 and 1 mM ZnS04 with p- nitrophenyl phosphorylcholine (pNP-PC) as a substrate at 37°C.
Surprisingly, it was found that a polypeptide having phospholipase C activity as disclosed herein, more efficiently degraded phospholipids such as phosphatidyl choline (PC), phosphatidyl ethanolamine (PE), phosphatidyl inositol (PI) and phosphatidic acid (PA) in a neutral environment than in a more acid environment in a high oil / low water composition. A high oil / low water composition comprises less than 10, 8, 6, or 4 wt% of water relative to oil.
A polypeptide as disclosed herein may be an isolated, substantially pure, pure, recombinant, synthetic or variant polypeptide or a non-naturally occurring polypeptide.
A polypeptide having phospholipase C activity according to the present invention is advantageously derived from a Hypocrea sp., eg. Hypocrea virens. The wording "derived" or "derivable" from, with respect to the origin of a polypeptide as disclosed herein, means that when carrying out a BLAST search with a polypeptide according to the present invention, the polypeptide according to the present invention may be derivable from a natural source, such as a microbial cell, of which an endogenous polypeptide shows the highest percentage homology or identity with the polypeptide as disclosed herein.
In one embodiment, a polypeptide of the invention having phospholipase C activity is not a native polypeptide of Hypocrea virens containing a native leader sequence. For instance, a polypeptide of the invention having phospholipase C activity is not the complete amino acid sequence of SEQ ID NO: 2. For instance, a polypeptide of the invention having phospholipase C activity is not the amino acid sequence consisting of amino acids 1 to 643 of SEQ ID NO: 2.
A polypeptide having phospholipase C activity (EC 3.1 .4.3) as disclosed herein is an enzyme that may hydrolyze phospholipids into diacylglyceride (DAG) and a phosphate from phosphatidic acid (PA), or DAG and a phosphate ester (from PC, PE and PI). Surprisingly, it was found that a polypeptide having phospholipase C activity according to the present invention has activity to the major phospholipids phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, and phosphatidic acid. An advantage of a polypeptide having activity to the major phospholipids is that only one phospholipase enzyme may be needed to hydrolyze all phospholipids into diglyceride and phosphate or phosphate ester, such as in a vegetable oil degumming process for efficient removal of phospholipids. A phospholipase as disclosed herein may have
phosphatase activity E.C. 3.1 .3. A phosphatase catalyzes the conversion of a phosphate ester, for instance the conversion of phosphate esters PC PE and PI into phosphate and choline, ethanol amine and inositol, respectively.
A polypeptide of SEQ ID NO: 2 comprises a leader sequence for secretion of the polypeptide outside cell. A leader sequence in SEQ ID NO: 2 may comprise amino acids 1 to 15, or 1 to 16, or 1 to 17, or 1 to 18 or 1 to 19, wherein the methionine (M) at position 1 is counted as 1 .
A mature polypeptide sequence of SEQ ID NO: 2 as disclosed herein may comprise the amino acids from position 16, 17, 18, 19, or 20 to position 638, 639, 640, 641 , 642 or 643 of SEQ ID NO: 2 wherein the methionine (M) at position 1 is counted as 1 . For example a mature polypeptide of SEQ ID NO: 2 may comprise the amino acids from position 19 to position 643 of SEQ ID NO : 2, or is amino acids 19 to 643 of SEQ ID NO: 2, wherein the methionine (M) at position 1 is counted as 1 . A polypeptide that has least 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the mature polypeptide sequence of SEQ ID NO: 2, may be a polypeptide that has at least 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to amino acids 19 to 643 of SEQ ID NO: 2.
A polypeptide according to the present disclosure may advantageously be an isolated, substantially pure, pure, recombinant, synthetic or variant polypeptide of the polypeptide as defined herein. A polypeptide as disclosed herein may be purified. Purification of protein is known to a skilled person in the art, and may for instance comprise steps as separating proteins from cells or cell fractions, for instance by centrifugation, ammonium sulphate precipitation, ultracentrifugation, chromatography, or filtration, or ultrafiltration.
In one aspect the present disclosure relates to a composition comprising a polypeptide as disclosed herein. A composition as disclosed herein, may comprise a carrier, an excipient, an auxiliary enzyme, or other compounds. Typically a composition, or a formulation, comprises a compound with which a polypeptide having phospholipase C activity may be formulated. An excipient as used herein is an inactive substance formulated alongside with a polypeptide as disclosed herein, for instance sucrose or lactose, glycerol, sorbitol or sodium chloride. A composition comprising a polypeptide as disclosed herein may be a liquid composition or a solid composition. A liquid composition, typically an aqueous solution, usually comprises water. When formulated as a liquid composition, the composition usually comprises components that
lower the water activity, such as glycerol, sorbitol or sodium chloride (NaCI). A solid composition comprising a polypeptide as disclosed herein may comprise a granulate comprising the enzyme or the composition comprises an encapsulated polypeptide in liquid matrices like liposomes or gels like alginate or carrageenans, or (synthetic. resins or silicas). There are many techniques known in the art to encapsulate or granulate a polypeptide or enzyme (see for instance G.M.H. Meesters, "Encapsulation of Enzymes and Peptides", Chapter 9, in N.J. Zuidam and V.A. Nedovic (eds.) "Encapsulation Technologies for Active Food Ingredients and food processing" 2010).
A composition as disclosed herein may also comprise a carrier comprising a polypeptide as disclosed herein. A polypeptide as disclosed herein may be bound or immobilized to a carrier by known technologies in the art, for instance by immobilizing the polypeptide on a carrier such as alginate or carrageenan. A composition as disclosed herein may also comprise an auxiliary enzyme, for instance a phospholipase A, or a PI-PLC. Alternatively, a composition as disclosed herein may comprise other enzymes that may be beneficial to enzyme assisted oil-degumming or refining. For instance a composition as disclosed herein may comprise one or more further enzyme(s) such as proteases, a chlorophyllases, pheophytinases, carbohydrases, for instance cell wall degrading enzymes such as cellulases, hemicellulases, pectinases and/ or β-glucosidases, and / or lipases.
A composition comprising a polypeptide having phospholipase C activity as disclosed herein may also be a fermentation broth comprising the polypeptide. A composition may comprise a polypeptide having phospholipase C activity wherein the polypeptide is bound to cells or cell material. Alternatively, cells or cell material have been removed from the fermentation broth by centrifugation. Optionally, cells are killed for instance by a heating step.
The present invention also relates to a process for preparing a composition comprising a polypeptide as disclosed herein, which may comprise spray drying a fermentation medium comprising the polypeptide, or granulating, or encapsulating a polypeptide as disclosed herein, and preparing the composition. Spray drying is known to a skilled person and usually comprises producing a dry powder from a liquid or slurry comprising a polypeptide as disclosed herein by rapidly drying with hot gas.
In another embodiment the present invention relates to a nucleic acid encoding a polypeptide having phospholipase C activity as disclosed herein, which has at least
85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 1 or to the mature polypeptide encoding sequence of SEQ ID NO: 1 .
A nucleic acid of the present disclosure may be an isolated, substantially pure, pure, recombinant, synthetic or variant nucleic acid of the nucleic acid or a non- naturally occurring nucleic acid. A polynucleotide sequence as disclosed herein may comprise SEQ ID NO: 1 , or may comprise the mature polypeptide encoding sequence of SEQ ID NO:1 .
In one other embodiment of the present invention a nucleic acid is disclosed that is an isolated, substantially pure, pure, recombinant, synthetic or variant nucleic acid of the nucleic acid of SEQ ID NO: 1 . A variant nucleic acid sequence may for instance have at least 80% sequence identity to SEQ ID NO:1.
In another aspect, the present invention relates to an expression vector comprising a nucleic acid as disclosed herein operably linked to one or more control sequence(s) that direct expression of the polypeptide in an expression host cell.
An expression vector may be obtained for instance by inserting a nucleic acid of the present invention into an empty construct or vector. There are several ways of inserting a nucleic acid into a nucleic acid construct or an expression vector which are known to a skilled person in the art, see for instance Sambrook & Russell, Molecular Cloning: A Laboratory Manual, 3rd Ed., CSHL Press, Cold Spring Harbor, NY, 2001 . It may be desirable to manipulate a nucleic acid encoding a polypeptide of the present invention with suitable control sequences. For instance the one or more control sequence(s) in an expression vector as disclosed herein may comprise a promoter sequence, a terminator sequence, and / or a leader sequence. .
A promoter may be any appropriate promoter sequence suitable for a eukaryotic or prokaryotic host cell, which shows transcriptional activity, including mutant, truncated, and hybrid promoters, and may be obtained from polynucleotides encoding extracellular or intracellular polypeptides either endogenous (native) or heterologous (foreign) to the cell. The promoter may be a constitutive or inducible promoter. Preferably, the promoter is an inducible promoter, for instance a starch inducible promoter. Promoters suitable in filamentous fungi are promoters which may be selected from the group, which includes but is not limited to promoters obtained from the polynucleotides encoding A. oryzae TAKA amylase, Rhizomucor miehei aspartic proteinase, Aspergillus gpdA promoter, A. niger neutral alpha-amylase, A. niger acid stable alpha-amylase, A. niger or A. awamori glucoamylase (glaA), A. niger
or A. awamori endoxylanase (xlnA) or beta-xylosidase (x/nD), T reesei cellobiohydrolase I (CBHI), R. miehei lipase, A. oryzae alkaline protease, A. oryzae triose phosphate isomerase, A. nidulans acetamidase, Fusarium venenatum amyloglucosidase (WO 00/56900), Fusarium venenatum Dania (WO 00/56900), Fusarium venenatum Quinn (WO 00/56900), Fusarium oxysporum trypsin-like protease (WO 96/00787), Trichoderma reesei beta-glucosidase, Trichoderma reesei cellobiohydrolase I, Trichoderma reesei cellobiohydrolase II, Trichoderma reesei endoglucanase I, Trichoderma reesei endoglucanase II, Trichoderma reesei endoglucanase III, Trichoderma reesei endoglucanase IV, Trichoderma reesei endoglucanase V, Trichoderma reesei xylanase I, Trichoderma reesei xylanase II, Trichoderma reesei beta-xylosidase, as well as the NA2-tpi promoter (a hybrid of the promoters from the polynucleotides encoding A. niger neutral alpha-amylase and A. oryzae triose phosphate isomerase), and mutant, truncated, and hybrid promoters thereof.
Any terminator which is functional in a cell as disclosed herein may be used, which are known to a skilled person in the art. Examples of suitable terminator sequences in filamentous fungi include terminator sequences of a filamentous fungal gene, such as from Aspergillus genes, for instance from the gene A. oryzae TAKA amylase, the genes encoding A. niger glucoamylase (glaA), A. nidulans anthranilate synthase, A. niger alpha-glucosidase, trpC and/or Fusarium oxysporum trypsin-like protease.
In another embodiment the present invention relates to a recombinant host cell comprising a nucleic acid or an expression vector as disclosed herein. A suitable host cell may be a mammalian, insect, plant, fungal, or algal cell, or a bacterial cell. A suitable bacterial cell may be from the genera Bacillus, Streptomyces or Pseudomonas, for instance from the species B. amyloliquefaciens, B. licheformis, S. coeli color, or P. putida.
A suitable host cell may be a fungal cell, for instance from the genus Acremonium, Aspergillus, Chrysosporium, Fusarium, Myceliophthora, Penicillium, Rasamsonia, Talaromyces, Thielavia, Trichoderma, Saccharomyces, Kluyveromyces, Pichia, for instance Aspergillus niger, Aspergillus awamori, Aspergillus foetidus, A. oryzae, A. sojae, Talaromyces emersonii, Rasamsonia emersonii Chrysosporium lucknowense, Fusarium oxysporum, Myceliophthora thermophila, Thielavia terrestris or Trichoderma reesei or, Saccharomyces cerevisiae, Kluyveromyces lactis, Pichia
pastoris. Preferably, a recombinant or transgenic host cell for expression of a phospholipase C as disclosed herein is an Aspergillus niger.
The host cell may be genetically modified with a nucleic acid construct or expression vector as disclosed herein with standard techniques known in the art, such as electroporation, protoplast transformation or conjugation for instance as disclosed in Sambrook & Russell, Molecular Cloning: A Laboratory Manual, 3rd Ed., CSHL Press, Cold Spring Harbor, NY, 2001 .
In one aspect the present invention relates to a process for the production of a polypeptide as disclosed herein comprising cultivating a recombinant host cell as disclosed herein in a suitable fermentation medium under conditions conducive to the production of the polypeptide and producing the polypeptide. A skilled person in the art understands how to perform a process for the production of a polypeptide as disclosed herein depending on a host cell used, such as pH, temperature and composition of a fermentation medium. A suitable fermentation medium usually comprises nutrients such a nitrogen, a carbon source and other essential elements known to a skilled person in the art for cultivating a particular host cell.
Host cells can be cultivated in shake flasks, or in fermenters having a volume of 0.5 or 1 litre or larger to 10 to 100 or more cubic metres. Cultivation may be performed aerobically or anaerobically depending on the requirements of a host cell.
A process for preparing a polypeptide as disclosed herein may further comprise recovering the polypeptide from the fermentation medium. Recovering the polypeptide may comprise isolating the polypeptide. Recovering may be performed by known methods in the art for instance recovering may comprise filtration, ultrafiltration, microfiltration, centrifugation or chromatography.
In another aspect the present invention relates to a process for hydrolysing phospholipids comprising incubating the phospholipids with a polypeptide having phospholipase C activity as disclosed herein or a composition as disclosed herein, wherein the phospholipids are hydrolysed. Phospholipids that may be hydrolysed include phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidic acid, and/or phosphatidyl serine. Phospholipids may be derived from a vegetable oil or a fat, for instance an animal derived fat such a dairy fat. Surprisingly, it was found that at least part of the phospholipids phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidic acid and phosphatidyl serine were hydrolysed by a polypeptide having phospholipase C activity as disclosed herein.
A process for hydrolysing phospholipids may comprise a step wherein phospholipids are separated from an oil, for instance a vegetable oil, or from a fat, for instance a dairy fat, for instance by water degumming, resulting in phospholipid- containing gums and water-degummed oil; incubating the phospholipid-containing gums with a polypeptide having phospholipase C activity as disclosed herein, wherein phospholipids are hydrolysed. A neutral oil fraction is usually obtained upon hydrolysis of the phospholipids and can be separated from the phosphor-containing fraction. The neutral oil can be then be added to the water degummed oil, which increases the yield of the oil.
Incubating phospholipids with a polypeptide having phospholipase C activity may be performed at any suitable pH and temperature. A suitable pH may for instance be a pH of between 3 and 9, or a pH of between 4 and 8, or a pH of between 5 and 7, or a pH of between 6 and 8. A suitable temperature may be a temperature of between 20 and 80 °C, for instance between 30 and 70°C, such as between 40 and 60 °C or between 45 and 55 °C.
In another aspect the present invention relates to a process for degumming a vegetable oil comprising contacting a vegetable oil comprising one or more phospholipids with a polypeptide having phospholipase C activity as disclosed herein or a composition as disclosed herein, wherein the one or more phospholipids are hydrolysed into diacylglycerol and phosphate ester and / or phosphate, separating the phosphate ester and / or phosphate from the vegetable oil wherein a degummed vegetable oil is obtained. In a process for degumming as disclosed herein hydrolysing phospholipids means that at least part of the phospholipids is hydrolysed. For instance, at least a part of the phospholipids phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidic acid and / or phosphatidyl serine is hydrolysed.
Degumming a vegetable oil in a process as disclosed herein comprises reducing the phosphorus content in the vegetable oil. Advantageously, the atomic phosphorus content is reduced to less than 50 ppm P, or less than 20 ppm P or less than 10, or less than 5 ppm P, or less than 2 ppm P. The phosphorus content can be measured by standard ICP methods (inductively coupled plasma).
A vegetable oil in a process according to the present disclosure may be a crude oil or a previously degummed oil by other means, for instance by water degumming. A vegetable oil may also be obtained by pressing oil seed (pressed oil or expeller), by hexane extraction of oil seed. A vegetable oil may for instance be canola oil, castor oil,
coconut oil, corn oil, cotton oil palm oil, palm kernel oil, peanut oil, rapeseed oil, rice bran oil, soybean oil or sunflower oil.
A process for degumming a vegetable oil as disclosed herein may further comprise a step of separating the degummed vegetable oil from gums. Such separating may for instance be achieved by centrifugation.
Contacting a vegetable oil comprising phospholipids with a polypeptide having phospholipase C activity may be performed in any suitable way. A polypeptide having phospholipase C activity may be dissolved in an aqueous medium and brought into contact with the vegetable oil by mixing or stirring, for instance by high-shear mixing.
A process for degumming a vegetable oil may be carried out at a pH of between 3 and 9, or a pH between 4 and 8, or a pH between 5 and 7, or a pH between 4 and 6, or a pH of between 3 and 7. The pH can be adjusted by known methods in the art for instance by the addition of acids, such as citric or phosphoric acid, optionally subsequently or simultaneously adding caustic such as sodium hydroxide. Advantageously phospholipids are hydrolysed at an acid pH value, since when phospholipids are hydrated they are more easily hydrolysed.
The temperature at which a process for degumming is carried out may be between 20 and 90 °C, or between 25 and 80 °C, such as between 30 and 70 °C, or between 40 and 60 °C, for instance between 45 and 55 °C, for instance at a temperature of between 50 and 90 °C. It was found advantageous to carry out a process for degumming at an elevated temperature, because the removal of gums rich in phosphorous-containing compounds by centrifugation is mostly done at elevated temperatures, such as 80°C. If the enzyme-assisted hydrolysis of phospholipids is performed at elevated temperature such as between 70 and 90 °C, the temperature of the oil does not need to be lowered after hexane extraction or pressing and before enzyme-assisted hydrolysis.
In one aspect the present invention relates to a degummed vegetable oil obtainable by a process as disclosed herein.
The following examples illustrate the invention.
EXAMPLES
MATERIALS and METHODS
Example 1. Cloning and Expression of phospholipase C
A polypeptide of Hypocrea virens of SEQ ID NO: 2, (L061 sequence) comprises a signal sequence of 18 amino acids for efficient secretion in Hypocrea virens, and a deduced mature protein sequence of 625 amino acids.
A codon-adapted DNA sequence for expression of the protein in Aspergillus niger was designed containing additional restriction sites for subcloning in an Aspergillus expression vector. Codon adaptation was performed as described in WO2008/000632. The codon optimized DNA sequence for expression of the gene encoding the L061 protein of SEQ ID NO: 2 in A. niger is shown in SEQ ID NO: 1 .
The translational initiation sequence of the glucoamylase glaA promoter was modified into 5'-CACCGTCAAA ATG-3' (SEQ ID NO:3) and an optimal translational termination sequence 5'-TAAA-3' was used in the generation of the expression constructs (as also detailed in WO2006/077258). A DNA fragment (SEQ ID NO: 4), containing a.o. part of the glucoamylase promoter and the PLC encoding genes, was synthesized completely, purified and digested with EcoRI and Pad.
The pGBTOP-16 vector (Figure 1 ) was linearized by EcoR\/Pac\ digestion and the linearized vector fragment was subsequently purified by gel-extraction. The DNA fragments were cloned into the pGBTOP-16 vector and the resulting vector was named pGBTOPL061 . Subsequently, A. niger GBA 306 was transformed with pGBTOPL061 in a co-transformation protocol with pGBAAS-4, with strain and methods as described in WO 201 1/009700 and references therein, and selected on acetamide containing media and colony purified according to standard procedures. Transformation and selection was performed as described in WO 98/46772 and WO 99/32617. Strains containing the L061 gene were selected via PCR with primers amplifying the introduced L061 gene to verify presence of the pGBTOPL061 expression cassette. A single transformant expressing NBL-L061 was selected, and further replica-plated to obtain a single strain inoculum.
Example 2: Fermentation of A niger NBL-L061 strain
Fresh A. niger NBL-L061 spores were prepared and used for generating sample material by cultivation of the strain in 24 deep well plates (Axygen, Union City, USA) containing 3 ml fermentation medium 2 (15 % w/v maltose, 6 % w/v bacto-soytone, 1 .5 % w/v (NH4)2S04, 0.1 % w/v NaH2P04.H20, 0.1 % w/v MgS04.7H20, 0.1 % w/v L- arginine, 8 %o w/v Tween-80, 2 %o w/v Basildon, 2 % w/v MES, pH 5.1 ). The 24 deep
well plates were covered with a Breathseal (Greiner bio-one, Frickenhausen, Germany) and a lid. After 6 days of growth at 34°C, 550 rpm and 80% humidity in a Microton incubator shaker (Infors AG, Bottmingen, Switzerland) 1 .5 mL samples were taken, the mycelium was separated from the supernatant by centrifugation for 30 min at 4000g and the supernatants were stored at -20°C until further analyses.
Example 3. Activity determination of phospholipase L061
3.1. Phospholipase C (PLC) activity assay (for screening)
The PLC activity of the samples L061 A5 and C5 was determined using the chromogenic substrate p-nitrophenyl phosphorylcholine (pNP-PC). The substrate solution consisted of 10 mM pNP-PC (Sigma N5879, Zwijndrecht, the Netherlands), 100mM acetate buffer
pH 5.0, 1 % Triton X-100 and 1 mM ZnS04. A mixture of 20 μΙ_ sample and 180 μΙ_ substrate solution was incubated at 37°C for 60 min. The reaction was stopped by adding 100 μΙ_ reaction mixture to 100 μΙ_ stop reagent containing 1 M TRIS and 50 mM EDTA adjusted to pH 10 with 2 M NaOH. A blank was made by adding the stop reagent before the enzyme sample. The optical density (OD) of samples and blanks were measured at 405 nm.
Calibration was performed by preparing pNP solutions of respectively 0 - 0.5 - 1 .0 - 2.0 - 2.9 - 4.0 mM in above mentioned buffer. 20 μΙ_ of each standard solution was mixed with 180 μΙ_ substrate and 100 μΙ_ of the mixture was added to 100 μΙ_ stop reagent. The OD of each solution was measured at 405 nm. By using linear regression, the slope of the calibration line was calculated.
Activity was calculated by using the following formula: ^ /mi = Δ^ΐορΙ
-lAbS (Asamp|e - Ablank)
Df = dilution factor of sample
slope = slope of p-nitro-phenol calibration curve (mL^mol) t = incubation time assay (60 min)
One U is defined as the amount of enzyme that liberates 1 μηηοΙ p-nitrophenol per minute under the conditions of the test (pH 5, 37°C).
3.2. Phospholipase C (PLC) activity assay (for general activity measurement)
The PLC activity of samples L061 SF1 , SF2 and SF3 was determined as described under 3.1. with the exception that an acetate buffer with 0.2% Triton X-100 was used
and a mixture of 40 μΙ_ sample* and 960 μΙ_ substrate solution was incubated at 37°C for 30 min.
* The sample had been diluted in 100 mM acetate buffer pH 5.0 with 0.2% triton X-100 and 1 .0 mM Zinc sulfate. After centrifugation, the supernatant was used for the activity assay. The sample was diluted in such a way that the AAbs is between 0.1 and 1 .0. Accordingly, calibration was performed by preparing pNP solutions in 1000 μΙ and incubation was performed for 30 min.
3.3. Protein determination
Protein content was measured according the "Coomassie Plus protein kit" of Pierce (art. no. 23236).
See also internal method of analysis 2459 - Universal Bradford protein assay using Coomassie Plus assay reagent, manual method.
Results of the PLC activity assays, protein determinations and specific activity are given in Table 2a and Table 2b
Table 1 : Phospholipase C activity of different screening samples of Hypocrea virens gene codon optimized for and expressed in Aspergillus niger.
Table 2: Phospholipase C activity of different samples of the Hypocrea virens gene codon optimized and expressed in Aspergillus niger.
'Determined with SDS/PAGE, so only BS-PLC content
SF2 pure sup: supernatant from a shake flask production; SF1 cone is a concentrated version thereof; SF3 wh b is a third shake flask production, whole broth (without separation of the cell material from the supernatant. ). Shake flask productions were done in 100 mL flasks with about 50 gram of material in the same way as described for the small scale sample.
Example 4: Determination of pH and temperature profile
The pH profile of phospholipase L061 was determined in a solution of 10mM pNP-PC, 30 mM acetic acid, 30 mM MOPS, 30 mM MES, 0.2% triton X-100 and 1 mM ZnS04 adjusted with NaOH to a pH ranging from 4 to 7.5. Subsequently the same procedure as described in Example 3 was followed. A shake-flask-produced enzyme sample with an activity of 1 .0 U/mL was used.
The temperature profile phospholipase L061 was determined using the method of Example 3 at different temperatures, using an enzyme sample prepared by a shake flask fermentation with an activity of 0.06 U/mL.
The results in Table 3 and Table 4 show that the mature phospholipase L061 according to SEQ ID NO: 2 has a pH optimum of about 5.0 and a temperature optimum of about 55°C.
Table 3: pH profile of phospholipase L061 (pH optimum is set at 100%)
Table 4: Temperature profile of phospholipase L061 (temperature optimum
100%)
relative activity
Temperature (°C)
(%)
20.1 14.3
30.1 33.4
37.2 56.0
43.9 80.6
47.8 93.7
52.0 96.4
55.0 100.0
60.1 73.9
65.0 29.7
69.8 7.0
Example 5. Hydrolysis of phospholipids in a dispersion of de-oiled lecithin in water at pH 5 and 6 and 60°C
5.1. General method:
10 wt % of de-oiled lecithin [DOL, Lecisoya P97IP, Novastell, France] was dispersed in a buffer, a 10 mM citrate buffer for pH 4 and 10 mM phosphate buffer for pH 6, using an Silverson L4RT dispersing device, room temperature 3 minutes 8000 rpm (80% of maximum). This was brought to 37°C and enzyme was added in 3, 4 or 5 wt%, the amount depending on the protein content. When the supernatant contained more than 1 .0 mg protein/ ml_, only 3 wt% of the material was added to the DOL dispersion, for a level between 0.5 and 1 .0 mg/mL 4 wt% was added, for a level below 0.5 mg/mL 5 wt% was added.
This dispersion was stirred at 37°C or 60°C for 24 hrs. After 4 and 24 hours a sample was taken. The sample was immediately heat treated to inactivate the enzyme by holding the sample for 5 minutes in a boiling water bath. Subsequently the samples were kept frozen until analysis by 31 P NMR.
5.2. 31 P NMR method
For 31P NMR 10 μΙ_ of 10% DOL dispersion was dispersed in 1 mL of an aqueous solvent containing demineralized water with 10% deuterium oxide (D20, Cambridge Isotope Laboratories, DLM-4), 25 mg/mL deoxycholic acid (Sigma D2510), 5.84 mg/mL EDTA di Na (Titriplex III, Merck 108418), and 5.45 mg/mL TRIS base (Tris(hydroxymethyl) aminomethane, Merck 108387), of which the pH was adjusted to pH 9 using 4N KOH and to which 2 mg/mL TIP internal standard (tri- isopropylphosphate, Aldrich 554669) (accurately weighed) was added.
All samples were measured in a Bruker 400 MHz Avancelll NMR spectrometer with a Prodigy BBO probe. The temperature of the probe head was set at 300K.
The measurement for quantification was performed with semi-quantitative parameters: 128 scans, 90°pulse, D1 = 5sec. Values are reported in μη-iol/g of dry weight (DOL) of the sample.
5.3. Incubation of L061 in a dispersion of de-oiled lecithin at 60°C
5 wt% of supernatant from sample L061 (Hypocrea virens; sample A5) was added to a DOL dispersion as described above, at pH 5 and 6. The DOL dispersion obtained after incubation for 24 hours and after inactivation of the enzyme was analysed by 31P NMR. The 31 P NMR results are given in the following table, compared to the reference DOL dispersion kept for 24hr at 60°C at the same pH, in μηΊθΙ/g and in mol% (free phosphate levels excluded from mol% calculations).
Table 5. Composition of de-oiled lecithin (DOL) incubated with L061 phospholipase at pH 5 and 6 at 60°C for 24 hr.
The values in the table show that a phospholipase C L061 shows activity on PA, PC, PE and PI, at 60°C and pH 5 and 6. Activity was also seen after 4 hours, after which hydrolysis had proceeded to 20-40% (values not reported).
Example 6. Hydrolysis of phospholipids in crude soybean oil at neutral conditions
100 gram crude soy bean oil (North American Expander, with about 2.16 wt% of total phospholipids - measured by N MR, see below) was brought to a temperature of 55°C and first treated with 130 ppm NaOH (55°C for 30 minutes), then 2.5% of water was added with enzyme obtained from shake flask fermentation (with 17.1 U/mL, see Example 3 above) at 3.14μΙ_^ oil. This corresponds to 2.5 U PLC per gram
phospholipid At time points 0.5, 2, 4 and 24 hr a sample was taken and the
composition of phosphorous compounds was analyzed by 31 P NMR and diacylglyceride (DAG) levels by H PLC.
31 P N MR characterization was done in a slightly different protocol than as described in example 5.
In the present example the TIP/TMP internal standard solution was prepared by mixing 100mM Triisopropyl phosphate (TI P, 97%, Aldrich, #554669) and Trimethylphosphate (TMP, 99+%, Aldrich, #241024) solutions in 2-propanol (I PA, HPLC grade, J.T. Baker, #9095-33) respectively, at a ratio of 1 : 1 .
An extraction buffer was made with the same composition as the NMR solvent used for Example 5, except that the pH was brought to 10.5 using solid KOH. The extraction buffer was used to extract the phospholipids from the oil: An aliquot of -220 L of well stirred oil was weighed accurately into a 2 mL tube. 100 μί D20, and 900 μί extracting buffer were added to the tube. The sample was mixed at room temperature and 1400rpm for 60 minutes (benchtop Eppendorf Thermomixer R). After 60 minutes, the sample was centrifuged in a benchtop Eppendorf 5417C centrifuge at 14000rpm for 10 minutes. 600 μί of the aqueous extraction layer was transferred into a new tube, followed by accurate addition of 24 μί of the TIP/TMP standard solution to the sample. The mixture was mixed using a benchtop vortex for 15 seconds. 500 μΙ_ of this sample (accurately) was transferred into a clean NMR tube. NMR measurements were performed using a Bruker AVANCE™ 500 MHz NMR with QNP 500MHz S2 5mm probe with Z-gradient, using the 31 P Channel at 202.4Hz and proton decoupling. The temperature was set at 300K. The number of scans was typically set at 512, and a relaxation delay at 0.1 s.
Diacylglyceride levels were determined using a variant of the AOCS Official Method Cd 1 1 d-96 by H PLC-ELSD, using an Agilent 1260 HPLC system with Agilent 380 - ELSD and Agilent Prep-SIL Scalar HPLC column (4.6 x 150 mm, 10 μηι particle
size; part# 443910-901 ). Materials: Chemicals EMD Hexanes, part# HX0290P-1 , EMD Ethyl Acetate, part# EX0245P-1 , EMD Isopropyl Alcohol (IPA), part# PX1838P-1 , EMD formic acid 98-100 %, part# 1 1 16701000, Sigma Aldrich 1 ,2-Dipalmitoyl-rac-glycerol, ≥99%, part# D2135-1 G, Sigma Aldrich Glyceryl 1 ,3-dipalmitate,≥99%, part# D1639- 1 G.
HPLC settings: Mobile phase A: Hexane / Mobile phase B: Hexane:lsopropanol:Ethyl Acetate:Formic Acid:800: 100: 100:1 and an elution gradient as follows:
Solvent Flow Rate: 2 mL/min, Operating Pressure: -30 bar; Column temperature: 40.0°C; Injection Volume: 5.00 μΙ_
Preparation of Oil Samples: An aliquot of 50 μΙ_ oil sample was brought into 2 ml_ HPLC vial, accurately weighed and subsequently 950 μΙ_ hexane/isopropanol (9:1 ) mixture was added to each oil sample. The sample was thoroughly mixed using a bench-top vortexer. This was measured against a standard from 1 ,2 DAG and 1 ,3 DAG in a 9:1 hexane:IPA mixture.
The results in Tables 6 and 7 show that the polypeptide of the present disclosure had activity towards all phospholipids PA, PE, PI and PC present in crude soy bean oil under neutral conditions. Table 8 shows that the 1 ,2 diacylglyceride production ran parallel with the breakdown of intact phospholipids. These results as well as the decrease of intact phospholipid levels show that a polypeptide having phospholipase C activity according to the present invention is capable of increasing the oil yield in an enzymatic degumming process under neutral conditions.
Table 6. Amount (in μΜ) of phospholipids, phosphate and phosphate esters in soybean oil incubated with phospholipase L061 versus time . P04 is the reaction product of the hydrolysis of PA. At t=0 there is already some P04 present in the starting oil
Time PA PE PI PC P04 EP IP CP
(h)
0 866 1496 1202 2153 301 0 0 0
0.5 739 1572 1072 1979 447 35 147 394
2 723 1649 792 1495 739 143 494 1069
4 587 1425 602 973 903 250 533 1356
24 238 636 429 106 1604 832 600 1998
Table 7. Amount of intact phospholipids in soybean oil incubated with phospholipase L061 versus time in mol%
Table 8. 1 ,2-diacylglyceride and 1 ,3 diacylglyceride level in soybean oil incubated with phospholipase L061 in wt% versus time
Example 7. Hydrolysis of phospholipids in crude soybean oil at slightly acidic conditions
A second reaction was run in the same way as described in the previous example, however now the oil was pretreated with 500ppm citric and 138ppm NaOH for acidic conditions and an enzyme concentration of 2.90 μΙ_ / g oil, which corresponds to 2.3 U/g phospholipid was added.
The results in Tables 9 and 10 show that the polypeptide having phospholipase according of the present disclosure had activity towards all phospholipids PA, PE, PI and PC present in crude soy bean oil under acid conditions. Table 1 1 shows that the 1 ,2 diacylglyceride production ran parallel with the breakdown of intact phospholipids.
Table 9. Amount (in μΜ) of phospholipids, phosphate and phosphate esters in soybean oil incubated with phospholipase L061 versus time
Table 10. Amount (in mol%) of intact phospholipids in soybean oil incubated with phospholipase L061 versus time
Table 11. Diacylglyceride level (wt%) phospholipids in soybean oil incubated with phospholipase L061 versus time
The results in Example 6 and 7 show that a phospholipase of the present disclosure hydrolysed a higher amount of the phospholipids phosphatidyl choline, phosphatidyl ethanol amine, phosphatidyl inositol phosphatidic acid under neutral conditions than under acidic conditions.
Example 8 - Hydrolysis of phospholipids in rape seed oil
Extracted rape seed oil from European origin (100 mL) was pretreated with 200 ppm NaOH, and directly after that 5% w/w enzyme was added, that was obtained from a shake flask fermentation by treating broth with 10 mg Triton / gram broth, 60 min at room temperature and 10 minutes centrifugation at 4,000 rpm. The sample was sheared by a Silverson high shear mixer (1 minute at full speed) and left to incubate well stirred at 60°C for 24 hours. During incubation samples were drawn.
Samples were heat treated to inactivate the enzyme, frozen, freeze dried and treated with cold acetone to extract the polar lipids [10 mL acetone on 1 mL]. After drying the acetone precipitate was characterized by 31NMR as described in example 5. The results are shown in table 12 (for clarity the lysophospholipids and glycerophosphates compounds are left out).
Table 12. Phospholipid composition of extracted rapeseed oil incubated with phospholipase L061 versus time.
The results in Table 12 show that the enzyme can hydrolyze all phospholipids in rape seed oil.
Example 9. Hydrolysis of dairy phospholipids
Commercial dairy cream (Albert Heijn, Puur&Eerlijk) was freeze dried, washed with acetone to remove the non-polar lipids, redispersed in water and 5% enzyme solution obtained as described in Exampl 8 was added. After 4 hr at 50°C the sample was freeze dried.
This material was extracted with 3 ml CHCI3/MeOH on 100 mg dry sample weight. After taking out the extract/solvent the residue was washed with 2 ml CHCI3/MeOH, to yield the polar lipids and a part of the reaction products choline-phosphate, ethanolamine- phosphate, inositol phosphate and free phosphate (limited solubility in CHCI3/MeOH). These portions of CHCI3/MeOH were combined and dried under a stream of nitrogen. Subsequently the material was dissolved in the aqueous buffer and analyzed by 31 P NMR as described above.
The results in Table 13 show that phospholipase C of the present disclosure
hydrolyzes all phospholipids PC, PE, PI, PA and also phosphatidyl serine (PS).
Table 13. Amount of phospholipids and reaction products in extracted dairy cream after treatment with phospholipase of the present disclosure
In μη-iol/g
PC C-P PS PE E-P PI l-P PA
Ref 2.45 0.36 0.79 1 .28 0.21 0.60 0.10 0.07
PLC treated 0.06 2.62 0.00 0.14 3.21 0.02 0.19 0.03
n mol % total
PC C-P PS PE E-P PI l-P PA
Ref 24.3 3.6 7.9 12.7 2.1 5.9 1 .0 0.7 90.8
PLC treated 0.6 27.7 0.0 1 .5 33.9 0.2 2.1 0.3 93.0
Claims
1 . A polypeptide having phospholipase C activity, selected from the group consisting of
i. a polypeptide comprising a mature polypeptide sequence of SEQ ID NO: 2;
ii. a polypeptide that has least 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to the mature polypeptide sequence of SEQ ID NO: 2;
iii. a polypeptide encoded by a nucleic acid that hybridizes under medium stringency, preferably under high stringency conditions to the complementary strand of the mature polypeptide coding sequence of SEQ ID NO:1 ;
iv. a polypeptide encoded by a nucleic acid that has at least 85%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity to the mature polypeptide coding sequence of SEQ ID NO: 1 .
2. A polypeptide that is an isolated, substantially pure, pure, recombinant, synthetic or variant polypeptide of the polypeptide of claim 1.
3. A polypeptide according to claim 1 or 2, wherein the polypeptide comprises activity towards phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl serine and/or phosphatidic acid.
4. A composition comprising a polypeptide according to any one of the claims 1 to 3.
5. A composition according to claim 4, further comprising a carrier, an excipient, or an auxiliary enzyme.
6. A nucleic acid encoding a polypeptide having phospholipase C activity according to claim 1 to 3, which has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 1 or to the mature polypeptide encoding sequence of SEQ ID NO: 1 .
7. A nucleic acid that is an isolated, substantially pure, pure, recombinant, synthetic or variant nucleic acid of the nucleic acid of claim 6
8. An expression vector comprising a nucleic acid according to claim 6 or 7 operably linked to one or more control sequence(s) that direct expression of the polypeptide in a host cell.
9. A recombinant host cell comprising a nucleic acid according to claim 6 or 7, or an expression vector according to claim 8.
10. A method for preparing a polypeptide according to claims 1 to 3, comprising cultivating a host cell according to claim 9 in a suitable fermentation medium, under conditions that allow expression of the polypeptide, thereby to prepare the polypeptide.
1 1 . A process for hydrolysing one or more phospholipids comprising incubating the one or more phospholipids with a polypeptide having phospholipase C activity according to claims 1 to 3, or a composition according to claim 4 or 5, wherein the one or more phospholipids are hydrolysed.
12. A process according to claim 1 1 , wherein the one or more phospholipids comprise phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl serine and/or phosphatidic acid.
13. A process for degumming a vegetable oil comprising contacting a vegetable oil comprising one or more phospholipids with a polypeptide having phospholipase C activity according to any one of the claims 1 to 3 or a composition according to claim 4 and 5, wherein the one or more phospholipids are hydrolysed into diacylglycerol and phosphate ester and / or phosphate, separating the phosphate ester and / or phosphate from the vegetable oil wherein a degummed vegetable oil is obtained.
14. A process for degumming according to claim 13, wherein the one or more phospholipids are hydrolysed at a pH value of between 3 and 9.
15. A process according to any one of the claims claim 13 or 14, wherein the one or more phospholipids phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl serine and/or phosphatidic acid are hydrolysed.
16. A degummed vegetable oil obtainable by a process according to any one of the claims 13 to 15.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/564,275 US10457890B2 (en) | 2015-04-09 | 2016-04-08 | Phospholipase C |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15162972 | 2015-04-09 | ||
EP15162972.2 | 2015-04-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016162456A1 true WO2016162456A1 (en) | 2016-10-13 |
Family
ID=52823515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2016/057690 WO2016162456A1 (en) | 2015-04-09 | 2016-04-08 | Phospholipase c |
Country Status (3)
Country | Link |
---|---|
US (1) | US10457890B2 (en) |
AR (1) | AR104205A1 (en) |
WO (1) | WO2016162456A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018171552A1 (en) * | 2017-03-20 | 2018-09-27 | Novozymes A/S | Method for degumming and refining of vegetable oil |
WO2018200464A1 (en) | 2017-04-25 | 2018-11-01 | Bunge Oils, Inc. | Process for enzymatic degumming |
WO2019215078A1 (en) | 2018-05-07 | 2019-11-14 | Dsm Ip Assets B.V. | Process for enzymatic oil degumming |
WO2023208768A1 (en) | 2022-04-26 | 2023-11-02 | Dsm Ip Assets B.V. | Method of producing cannabis distillate |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996000787A1 (en) | 1994-06-30 | 1996-01-11 | Novo Nordisk Biotech, Inc. | Non-toxic, non-toxigenic, non-pathogenic fusarium expression system and promoters and terminators for use therein |
WO1998046772A2 (en) | 1997-04-11 | 1998-10-22 | Dsm N.V. | Gene conversion as a tool for the construction of recombinant industrial filamentous fungi |
WO1999032617A2 (en) | 1997-12-22 | 1999-07-01 | Dsm N.V. | Expression cloning in filamentous fungi |
WO2000056900A2 (en) | 1999-03-22 | 2000-09-28 | Novo Nordisk Biotech, Inc. | Promoter sequences derived from fusarium venenatum and uses thereof |
WO2006077258A1 (en) | 2005-01-24 | 2006-07-27 | Dsm Ip Assets B.V. | Method for producing a compound of interest in a filamentous fungal cell |
WO2008000632A1 (en) | 2006-06-29 | 2008-01-03 | Dsm Ip Assets B.V. | A method for achieving improved polypeptide expression |
WO2008094847A1 (en) | 2007-01-30 | 2008-08-07 | Bunge Oils, Inc. | Enzymatic degumming utilizing a mixture of pla and plc phospholipases |
WO2011009700A1 (en) | 2009-07-22 | 2011-01-27 | Dsm Ip Assets B.V. | Improved host cell for the production of a compound of interest |
WO2011046815A1 (en) | 2009-10-16 | 2011-04-21 | Bunge Oils, Inc. | Oil degumming methods |
WO2012062817A1 (en) | 2010-11-12 | 2012-05-18 | Novozymes A/S | Polypeptides having phospholipase c activity and polynucleotides encoding same |
WO2014090161A1 (en) | 2012-12-11 | 2014-06-19 | Novozymes A/S | Polypeptides having phospholipase c activity and polynucleotides encoding same |
-
2016
- 2016-04-07 AR ARP160100944A patent/AR104205A1/en unknown
- 2016-04-08 US US15/564,275 patent/US10457890B2/en active Active
- 2016-04-08 WO PCT/EP2016/057690 patent/WO2016162456A1/en active Application Filing
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996000787A1 (en) | 1994-06-30 | 1996-01-11 | Novo Nordisk Biotech, Inc. | Non-toxic, non-toxigenic, non-pathogenic fusarium expression system and promoters and terminators for use therein |
WO1998046772A2 (en) | 1997-04-11 | 1998-10-22 | Dsm N.V. | Gene conversion as a tool for the construction of recombinant industrial filamentous fungi |
WO1999032617A2 (en) | 1997-12-22 | 1999-07-01 | Dsm N.V. | Expression cloning in filamentous fungi |
WO2000056900A2 (en) | 1999-03-22 | 2000-09-28 | Novo Nordisk Biotech, Inc. | Promoter sequences derived from fusarium venenatum and uses thereof |
WO2006077258A1 (en) | 2005-01-24 | 2006-07-27 | Dsm Ip Assets B.V. | Method for producing a compound of interest in a filamentous fungal cell |
WO2008000632A1 (en) | 2006-06-29 | 2008-01-03 | Dsm Ip Assets B.V. | A method for achieving improved polypeptide expression |
WO2008094847A1 (en) | 2007-01-30 | 2008-08-07 | Bunge Oils, Inc. | Enzymatic degumming utilizing a mixture of pla and plc phospholipases |
WO2011009700A1 (en) | 2009-07-22 | 2011-01-27 | Dsm Ip Assets B.V. | Improved host cell for the production of a compound of interest |
WO2011046815A1 (en) | 2009-10-16 | 2011-04-21 | Bunge Oils, Inc. | Oil degumming methods |
WO2012062817A1 (en) | 2010-11-12 | 2012-05-18 | Novozymes A/S | Polypeptides having phospholipase c activity and polynucleotides encoding same |
WO2014090161A1 (en) | 2012-12-11 | 2014-06-19 | Novozymes A/S | Polypeptides having phospholipase c activity and polynucleotides encoding same |
Non-Patent Citations (10)
Title |
---|
A. J. DIJKSTRA: "Enzymatic degumming", EUR. J. LIPID SCI. TECHNOL., vol. 112, 2010, pages 1178 - 1189 |
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10 |
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402 |
ANONYMOUS: "EM_EST:FG382111", 22 May 2008 (2008-05-22), XP055246415, Retrieved from the Internet <URL:http://ibis.internal.epo.org/exam/dbfetch.jsp?id=EM_EST:FG382111> [retrieved on 20160201] * |
ANONYMOUS: "UNIPROT:G9MH09", 22 February 2012 (2012-02-22), XP055277672, Retrieved from the Internet <URL:http://ibis/exam/dbfetch.jsp?id=UNIPROT:G9MH09> [retrieved on 20160603] * |
F. GALHARDO; C. DAYTON: "AOCS Lipid Library", 2012, article "Enzymatic Degumming" |
G.M.H. MEESTERS: "Encapsulation Technologies for Active Food Ingredients and food processing", 2010, article "Encapsulation of Enzymes and Peptides (chapter 9)" |
NEEDLEMAN, S. B.; WUNSCH, C. D., J. MOL. BIOL., vol. 48, 1970, pages 443 - 453 |
RICE,P.; LONGDEN,L.; BLEASBY,A.: "EMBOSS: The European Molecular Biology Open Software Suite", TRENDS IN GENETICS, vol. 16, no. 6, 2000, pages 276 - 277, Retrieved from the Internet <URL:http://emboss.bioinformatics.nl> |
SAMBROOK; RUSSELL: "Molecular Cloning: A Laboratory Manual, 3rd ed.", 2001, CSHL PRESS |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018171552A1 (en) * | 2017-03-20 | 2018-09-27 | Novozymes A/S | Method for degumming and refining of vegetable oil |
WO2018200464A1 (en) | 2017-04-25 | 2018-11-01 | Bunge Oils, Inc. | Process for enzymatic degumming |
US10501703B2 (en) | 2017-04-25 | 2019-12-10 | Bunge Oils, Inc. | Process for enzymatic degumming |
EP3401383A1 (en) | 2017-05-08 | 2018-11-14 | Bunge Oils, Inc. | Process for enzymatic degumming |
WO2019215078A1 (en) | 2018-05-07 | 2019-11-14 | Dsm Ip Assets B.V. | Process for enzymatic oil degumming |
WO2023208768A1 (en) | 2022-04-26 | 2023-11-02 | Dsm Ip Assets B.V. | Method of producing cannabis distillate |
Also Published As
Publication number | Publication date |
---|---|
AR104205A1 (en) | 2017-07-05 |
US10457890B2 (en) | 2019-10-29 |
US20180134986A1 (en) | 2018-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yu et al. | Purification and characterization of the extracellular lipase Lip2 from Yarrowia lipolytica | |
US10457890B2 (en) | Phospholipase C | |
US11999923B2 (en) | Process for enzymatic oil degumming | |
US20230332069A1 (en) | Method for Degumming and Refining of Vegetable Oil | |
Yan et al. | Expression and characterization of a novel 1, 3-regioselective cold-adapted lipase from Rhizomucor endophyticus suitable for biodiesel synthesis | |
CN113646076A (en) | Silica adsorbent treatment for removal of chlorophyll derivatives from triacylglycerol-based oils | |
WO2015144092A1 (en) | Polypeptides having phospholipase c activity and polynucleotides encoding same | |
US20230080079A1 (en) | Mutant lipase and use thereof | |
US10982171B2 (en) | Methods for oil degumming | |
CN106884008B (en) | Phospholipase, coding gene and preparation method thereof | |
US20230250406A1 (en) | Mutant lipase and use thereof | |
KR20210145198A (en) | Silica Adsorbent for Removal of Chlorophyll Derivatives from Triacylglycerol-Based Oils | |
US11447714B2 (en) | Enzymatic removal of chlorophyll substrates from triacylglycerol-based oils | |
Jia et al. | Production of l-α-Glycerylphosphorylcholine from Oil Refining Waste Using a Novel Cold-Active Phospholipase B from Bacillus velezensis | |
RU2772452C2 (en) | Method for removal of resinous substances from vegetable oil and its refining | |
EP4334467A1 (en) | Enzymatic treatment of feedstock for hydrotreated vegetable oil (hvo) production |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16718250 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15564275 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16718250 Country of ref document: EP Kind code of ref document: A1 |